<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia - El‐Sayeh, HG - 2018 | Cochrane Library</title> <meta content="Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia - El‐Sayeh, HG - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000458.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia - El‐Sayeh, HG - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000458.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000458.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia" name="citation_title"/> <meta content="Hany G El‐Sayeh" name="citation_author"/> <meta content="Tees, Esk &amp; Wear Valleys NHS Foundation Trust" name="citation_author_institution"/> <meta content="John Rathbone" name="citation_author"/> <meta content="Bond University" name="citation_author_institution"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="hbergman@cochrane.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD000458.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000458.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000458.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000458.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic Uptake Inhibitors [therapeutic use]; Anti‐Dyskinesia Agents [*therapeutic use]; Antipsychotic Agents [*adverse effects]; Celiprolol [therapeutic use]; Disease Progression; Dopamine Antagonists [therapeutic use]; Dyskinesia, Drug‐Induced [*drug therapy]; Haloperidol [therapeutic use]; Methyldopa [therapeutic use]; Randomized Controlled Trials as Topic; Reserpine [therapeutic use]; Tetrabenazine [therapeutic use]; Tiapamil Hydrochloride [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000458.pub3&amp;doi=10.1002/14651858.CD000458.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000458\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000458\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000458.pub3",title:"Non\\u2010antipsychotic catecholaminergic drugs for antipsychotic\\u2010induced tardive dyskinesia",firstPublishedDate:"Jan 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000458.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000458.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000458.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000458.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000458.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000458.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000458.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000458.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000458.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000458.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1443 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000458.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0217"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0105"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-sec-0192"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/appendices#CD000458-sec-0231"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/table_n/CD000458StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/table_n/CD000458StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#CD000458-cr-0002">Hany G El‐Sayeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#CD000458-cr-0003">John Rathbone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#CD000458-cr-0004">Karla Soares‐Weiser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information#CD000458-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Hanna Bergman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information/en#CD000458-sec-0244">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000458.pub3">https://doi.org/10.1002/14651858.CD000458.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000458-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000458-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000458-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000458-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000458-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000458-abs-0001" lang="en"> <section id="CD000458-sec-0001"> <h3 class="title" id="CD000458-sec-0001">Background</h3> <p>Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. </p> </section> <section id="CD000458-sec-0002"> <h3 class="title" id="CD000458-sec-0002">Objectives</h3> <p>1. To determine the effects of any of the following drugs for antipsychotic‐induced TD in people with schizophrenia or other chronic mental illnesses.<br/> i. Drugs which influence the noradrenergic system.<br/> ii. Dopamine receptor agonists.<br/> iii. Dopamine receptor antagonists.<br/> iv. Dopamine‐depletor drugs.<br/> v. Drugs that increase the production or release of dopamine. </p> <p>2. To examine whether any improvement occurred with short periods of intervention (less than 6 weeks) and, if this did occur, whether this effect was maintained at longer periods of follow‐up. </p> <p>3. To examine if there was a differential effect for the various compounds.</p> <p>4. To examine whether the use of non‐antipsychotic catecholaminergic drugs are most effective in those with more recent onset TD (less than five years). </p> </section> <section id="CD000458-sec-0003"> <h3 class="title" id="CD000458-sec-0003">Search methods</h3> <p>We retrieved 712 references from searching the Cochrane Schizophrenia Group Trials Register (July 2015 and April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. </p> </section> <section id="CD000458-sec-0004"> <h3 class="title" id="CD000458-sec-0004">Selection criteria</h3> <p>We selected studies if they were randomised controlled trials focusing on people with schizophrenia or other chronic mental illnesses and antipsychotic‐induced tardive dyskinesia. We compared the use of catecholaminergic interventions versus placebo, no intervention, or any other intervention for the treatment of antipsychotic‐induced tardive dyskinesia. </p> </section> <section id="CD000458-sec-0005"> <h3 class="title" id="CD000458-sec-0005">Data collection and analysis</h3> <p>We independently extracted data from these trials and we estimated risk ratios (RRs) with 95% confidence intervals (CIs). We assumed that people who left the studies early had no improvement. </p> </section> <section id="CD000458-sec-0006"> <h3 class="title" id="CD000458-sec-0006">Main results</h3> <p>There are 10 included trials (N = 261) published between 1973 and 2010; eight are new from the 2015 and 2017 update searches. Forty‐eight studies are excluded. Participants were mostly chronically mentally ill inpatients in their 50s, and studies were primarily of short (2 to 6 weeks) duration. The overall risk of bias in these studies was unclear, mainly due to poor reporting of allocation concealment and generation of the sequence. Studies were also not clearly blinded and we are unsure if data are incomplete or selectively reported, or if other biases were operating. </p> <p>One small, three‐arm trial found that both alpha‐methyldopa (N = 20; RR 0.33, 95% CI 0.14 to 0.80; <i>low‐quality evidence</i> ) and reserpine (N = 20; RR 0.52 95% CI 0.29 to 0.96; <i>low‐quality evidence</i> ) may lead to a clinically important improvement in tardive dyskinesia symptoms compared with placebo after 2 weeks' treatment, but found no evidence of a difference between alpha‐methyldopa and reserpine (N = 20; RR 0.60, 95% CI 0.19 to 1.86; <i>very low quality evidence</i> ). Another small trial compared tetrabenazine and haloperidol after 18 weeks' treatment and found no evidence of a difference on clinically important improvement in tardive dyskinesia symptoms (N = 13; RR 0.93, 95% CI 0.45 to 1.95; <i>very low quality evidence</i>). No study reported on adverse events. </p> <p>For remaining outcomes there was no evidence of a difference between any of the interventions: alpha‐methyldopa versus placebo for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; RR 0.33, 95% CI 0.02 to 7.32; <i>very low quality evidence</i> ), celiprolol versus placebo for leaving the study early (1 RCT; N = 35; RR 5.28, 95% CI 0.27 to 102.58; <i>very low quality evidence</i> ) and quality of life (1 RCT; N = 35; RR 0.87, 95% CI 0.68 to 1.12; <i>very low quality evidence</i> ), alpha‐methyldopa versus reserpine for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; not estimable, no reported events; <i>very low quality evidence</i> ), reserpine or carbidopa/levodopa versus placebo for deterioration of tardive dyskinesia symptoms (2 RCTs; N = 37; RR 1.18, 95% CI 0.35 to 3.99; <i>very low quality evidence</i> ), oxypertine versus placebo for deterioration of mental state (1 RCT; N = 42; RR 2.20, 95% CI 0.22 to 22.45; <i>very low quality evidence</i> ), dopaminergic drugs (amantadine, bromocriptine, tiapride, oxypertine, carbidopa/levodopa) versus placebo for leaving the study early (6 RCTs; N = 163; RR 1.29, 95% CI 0.65 to 2.54; <i>very low quality evidence</i>), and tetrabenazine versus haloperidol for deterioration of tardive dyskinesia symptoms (1 RCT; N = 13; RR 1.17, 95% CI 0.09 to 14.92) and leaving the study early (1 RCT; N = 13; RR 0.23, 95% CI 0.01 to 4.00). </p> </section> <section id="CD000458-sec-0007"> <h3 class="title" id="CD000458-sec-0007">Authors' conclusions</h3> <p>Although there has been a large amount of research in this area, many studies were excluded due to inherent problems in the nature of their cross‐over designs. Usually data are not reported before the cross‐over and the nature of TD and its likely response to treatments make it imprudent to use this data. The review provides little usable information for service users or providers and more well‐designed and well‐reported studies are indicated. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000458-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000458-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000458-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000458-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000458-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000458-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000458-abs-0003" lang="en"> <h3>Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia</h3> <p><b>Review question</b>. </p> <p>To determine if catecholaminergic drugs help in the treatment of tardive dyskinesia for people with schizophrenia or similar mental health problems. </p> <p><b>Background</b>. </p> <p>People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). The main treatment of schizophrenia is antipsychotic drugs. However, these drugs can have debilitating side‐effects. Tardive dyskinesia is an involuntary movement that causes the face, mouth, tongue and jaw to convulse, spasm and grimace. It is caused by long‐term or high‐dose use of antipsychotic drugs, is difficult to treat and can be incurable. One suggested treatment is to use medication that affects the catecholaminergic system, which is a group of brain chemicals. </p> <p><b>Study characteristics</b>. </p> <p>The review includes 10 small, short studies published mainly in the 1980s involving a total of 261 people. </p> <p><b>Key results</b>. </p> <p>One small study found that after 2 weeks' treatment both alpha‐methyldopa and reserpine may lead to clinically important improvement in tardive dyskinesia symptoms compared with placebo, but the quality of evidence was low. We are uncertain about the effect of reserpine versus alpha‐methyldopa; quality of evidence was very low. Another small trial compared tetrabenazine and haloperidol after 18 weeks' treatment, but again we are uncertain about the effect as the quality of evidence was very low. The included studies did not report on any harmful effects of the drugs. </p> <p><b>Quality of the evidence</b>. </p> <p>Evidence is weak, limited, short term, and small scale. It is not possible to recommend these drugs as a treatment for tardive dyskinesia and their use is entirely experimental. There is a need for larger and more rigorous research in the area. </p> <p>This plain language summary was adapted by the review authors from a summary originally written by Ben Gray, Senior Peer Researcher, McPin Foundation (<a href="http://mcpin.org/" target="_blank">mcpin.org/</a>). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000458-sec-0217" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000458-sec-0217"></div> <h3 class="title" id="CD000458-sec-0218">Implications for practice</h3> <section id="CD000458-sec-0218"> <section id="CD000458-sec-0219"> <h5 class="title">1. For people with antipsychotic‐induced tardive dyskinesia</h5> <p>These studies provide no useful information for service‐users. It is unlikely that these data will impact upon the uptake of established strategies for TD such as early detection, dose/drug modification, vitamin E and use of tetrabenazine. However, people with TD could consider these as other experimental treatments for which very little supportive data exist. Few data exist for any treatment for TD. </p> </section> <section id="CD000458-sec-0220"> <h5 class="title">2. For clinicians</h5> <p>These treatments are purely experimental. This does not mean that they are not viable choices. If the drugs are available, these treatments could be used, but it would be advisable to study use of these treatments within a real‐world randomised trial. </p> </section> <section id="CD000458-sec-0221"> <h5 class="title">3. For policy makers</h5> <p>There seem few implications for policy makers except that, perhaps, these compounds should only be used for TD within the context of a well‐designed randomised controlled trial. </p> </section> </section> <h3 class="title" id="CD000458-sec-0222">Implications for research</h3> <section id="CD000458-sec-0222"> <section id="CD000458-sec-0223"> <h5 class="title">1. General</h5> <p>The power of this review would have been greatly enhanced by better reporting of data. For example, none of the studies made explicit how randomisation was undertaken; and few studies provide data for before the first period of cross‐over. We realise that much of the work for these trials predates <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> — first published in <a href="./references#CD000458-bbs2-0066" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637‐9. [PUBMED: 8773637] ">Begg 1996</a> — and that it is only too easy to judge studies of the past by standards of today. Future studies, however, should report to a much higher standard than what we have seen in trials eligible for this review. </p> </section> <section id="CD000458-sec-0224"> <h5 class="title">2. Specific</h5> <p>Well‐designed randomised controlled trials, involving a large number of participants over protracted periods of time, are needed if we are to see if non‐antipsychotic catecholaminergic drugs could have a role in prevention and treatment of TD. Such studies are of importance to people with the problem, who have long been ignored (<a href="#CD000458-fig-0001">Figure 1</a>). </p> <section id="CD000458-sec-0225"> <h6 class="title">2.1 Use of cross‐over design</h6> <p>Despite a large number of studies initially highlighted in the search, the data available for this review are very limited. The large number of studies we found, together with the disparate nature of these compounds, highlights the effort as well as the frustration that has gone into researching this topic. As previously mentioned, it is difficult to draw conclusions from a study that only includes 12 participants (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>). It seems wasteful that so many studies were excluded because of inadequately designed cross‐over formats. Although there are certain advantages in using a cross‐over design in chronic conditions such as TD, there are also major disadvantages, one of which is the expected duration over which the drugs in question exert their actions. This cannot be considered as consisting solely of the time taken for the active drug to be removed from the bloodstream — the much longer period of time that these drugs may effect neurotransmitter or receptor function as well as structure must also be considered. It cannot be assumed that a washout period of a few weeks or less will adequately counteract these carry‐over effects. TD is also an unstable condition and people with TD may not remain compliant with medication. All these factors make the arguments for not using cross‐over methodology strong, despite the initial attraction (<a href="./references#CD000458-bbs2-0062" title="ArmitageP . Should we cross off the crossover?. Journal of Clinical Pharmacology1991;32:1‐2. ">Armitage 1991</a>; <a href="./references#CD000458-bbs2-0088" title="FleissJL . The crossover study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley &amp; Sons, 1984. ">Fleiss 1984</a>; <a href="./references#CD000458-bbs2-0114" title="PocockSJ . Crossover trials. Clinical trials. A practical approach. Chichester: John Wiley &amp; Sons, 1983. ">Pocock 1983</a>). </p> </section> <section id="CD000458-sec-0226"> <h6 class="title">2.2 Sample size</h6> <p>The results suggest that larger sample size should be used to provide more precise estimates of effect and to help avoid false conclusions about the effects of the proposed treatment. </p> </section> <section id="CD000458-sec-0227"> <h6 class="title">2.3 Length of study</h6> <p>Only one study included in this review used the intervention for more than five months (<a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). TD, however, is a chronic condition of insidious onset, the severity of which fluctuates spontaneously (<a href="./references#CD000458-bbs2-0061" title="Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>). Even if the compounds under investigation have a swift effect, it is the long‐term outcomes that must be considered of most clinical value. </p> </section> <section id="CD000458-sec-0228"> <h6 class="title">2.4 Outcomes</h6> <p>Scale‐derived data do have their place. It is important that a scale is validated for measuring changes secondary to treatment in those with TD. Many studies have not used clinically meaningful markers of outcome. They instead tend to either use obscure/modified ratings scales (such as SKAUB) (<a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>); or even more nebulous surrogate end‐point measures. Scale‐derived data do have their place, but it is important that a scale is validated for measuring changes secondary to treatment in those with TD. In addition, many of the outcomes we initially desired when we started this review have not been investigated. Finally, a service user consultation also informed the addition of outcomes of special importance to patients. We have reconsidered all these outcomes in case they were too ambitious and tried to tailor them to a real‐world pragmatic trial design (see <a href="#CD000458-tbl-0006">Table 2</a>). Future studies could be well served by using guidelines as described in the CONSORT statement (<a href="./references#CD000458-bbs2-0111" title="MoherD , SchulzKF , AltmanD . The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel‐Group Randomised Trials. Journal of the American Medical Association2001;285(15):1987‐91. ">Moher 2001</a>). These may help avoid some of the rectifiable flaws in the study methodologies and as a result allow more studies to be included in the final analyses. </p> <div class="table" id="CD000458-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggestions for design of future studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<br/> Blindness: double, tested.<br/> Duration: 12 months beyond end of intervention at least.<br/> Raters: independent. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with antipsychotic‐induced tardive dyskinesia.*<br/> Age: any.<br/> Sex: both.<br/> History: any.<br/> N = 300.** </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Non‐antipsychotic catecholaminergic compound. N = 150.<br/> 2. Placebo: N = 150. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***<br/> Adverse effects: no clinically significant extrapyramidal adverse effects ‐ any time period***, use of any antiparkinsonism drugs, other important adverse events.<br/> Leaving the study early.<br/> Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.<br/> Compliance with drugs.<br/> Economic evaluations: cost‐effectiveness, cost‐benefit.<br/> General state: relapse, frequency and intensity of minor and major exacerbations.<br/> Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<br/> Distress among relatives: binary measure.<br/> Burden on family: binary measure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. </p> <p>** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<br/> *** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate. </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000458-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000458-sec-0022"></div> <div class="table" id="CD000458-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Settings:</b> inpatients in Austria and the USA<br/> <b>Intervention:</b> NORADRENERGIC DRUGS (alpha‐methyldopa, celiprolol)<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NORADRENERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b><br/> (140 to 800) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/> (0.14 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated alpha‐methyldopa.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: deterioration</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (2 to 732) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/> (0.02 to 7.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated alpha‐methyldopa.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies rating this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies rating this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment: Leaving the study early</b> </p> <p>follow‐up: 13 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.28</b> <br/> (0.27 to 102.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated celiprolol.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No improvement in quality of life</b> </p> <p>follow‐up: 13 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>944 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>822 per 1000</b><br/> (642 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/> (0.68 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated celiprolol.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, blinding of outcome assessors was not described.<br/> <sup>2</sup> Downgraded one step for imprecision: few events and small sample size.<br/> <sup>3</sup> Downgraded two steps for imprecision: few events, small sample size and wide CI that includes both no effect and appreciable benefit for intervention group.<br/> <sup>4</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000458-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in the USA<br/> <b>Intervention:</b> NORADRENERGIC DRUGS (alpha‐methyldopa)<br/> <b>Comparison:</b> DOPAMINERGIC DRUGS (reserpine) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOPAMINERGIC DRUGS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NORADRENERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.60</b><br/> (0.19 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1,000<br/> (95 to 930) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: Deterioration</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Among the 20 participants no events were reported.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability of treatment: Leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately.<br/> <sup>2</sup> Downgraded two steps for imprecision: few events, very small sample size, and wide CI that includes both appreciable benefit and appreciable harm for intervention group as well as no effect.<br/> <sup>3</sup> Downgraded two steps for imprecision: no events were reported, effect estimate cannot be calculated. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000458-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Settings:</b> inpatients in the UK and the USA<br/> <b>Intervention:</b> DOPAMINERGIC DRUGS (carbidopa/levodopa, oxypertine, reserpine)<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DOPAMINERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b><br/> (290 to 960) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b> <br/> (0.29 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated reserpine.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: Deterioration</b> </p> <p>follow‐up: 2‐6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/> (58 to 665) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (0.35 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included studies evaluated reserpine and carbidopa/levodopa.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies rating this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General mental state: Deterioration</b> </p> <p>follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/> (10 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.2</b> <br/> (0.22 to 22.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated oxypertine.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment: Leaving the study early</b> </p> <p>follow‐up: 2‐24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/> (72 to 282) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> <br/> (0.65 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only two studies (59 participants) evaluating carbidopa/levodopa and oxypertine reported any events for this outcome. 4 studies evaluating amantadine, bromocriptine, and tiapride reported no events and consequently no estimates could be made for these 3 compounds. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was designated to be of importance, especially to patients. We found no studies rating this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, blinding of outcome assessors was not described.<br/> <sup>2</sup> Downgraded one step for imprecision: few events and small sample size.<br/> <sup>3</sup> Downgraded two steps for imprecision: few events, small sample size and wide CI that includes both no effect and appreciable benefit for intervention group.<br/> <sup>4</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, attrition was high (45%).<br/> <sup>5</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, attrition was high (45%) or unbalanced between groups (25% vs. 0%).<br/> <sup>6</sup> Downgraded one step for inconsistency: statistical heterogeneity was high (I² = 58%).<br/> <sup>7</sup> Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000458-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in the USA<br/> <b>Intervention:</b> DOPAMINERGIC DRUGS (tetrabenazine)<br/> <b>Comparison:</b> OTHER DRUGS (haloperidol) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OTHER DRUGS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOPAMINERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b><br/> (0.45 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>714 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1000<br/> (321 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: Deterioration</b> </p> <p>follow‐up: 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.17</b><br/> (0.09 to 14.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/> (13 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acceptability of treatment: Leaving the study early</b> </p> <p>follow‐up: 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.23</b><br/> (0.01 to 4.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (3 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately.<br/> <sup>2</sup> Downgraded two steps for imprecision: few events, very small sample size, and wide CI that includes both appreciable benefit and appreciable harm for intervention group as well as no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000458-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000458-sec-0023"></div> <section id="CD000458-sec-0024"> <h3 class="title" id="CD000458-sec-0024">Description of the condition</h3> <p>Since the 1950s, antipsychotic (or neuroleptic) medication has been extensively used to treat people with chronic mental illnesses, such as schizophrenia. These drugs can effectively control symptoms such as abnormal perceptions (hallucinations), disordered thinking and fixed false beliefs (delusions). In addition, maintenance therapy with antipsychotics is associated with a reduced risk of relapses (<a href="./references#CD000458-bbs2-0116" title="SchoolerNR , KeithSJ . Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin1993;29:431‐46. ">Schooler 1993</a>). Antipsychotic medication, however, has also been associated with a wide range of adverse effects, including movement disorders. The appearance of these movement disorders can contribute to poor compliance with antipsychotic treatment and hence relapse (<a href="./references#CD000458-bbs2-0065" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Academic Press. Harcourt Brace &amp; Company, Publishers, 1993. ">Barnes 1993</a>). </p> <p>Tardive dyskinesia (TD) is one such movement disorder and is characterised by abnormal, repetitive and involuntary movements (<a href="./references#CD000458-bbs2-0061" title="Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>). The clinical features include tongue protrusion, side‐to‐side or rotatory movement of the jaw, lip smacking, puckering and pursing, and rapid eye blinking (<a href="./references#CD000458-bbs2-0074" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). In some people rapid movements of the arms, legs, and trunk may also occur. TD is a chronic condition of insidious onset, the severity of which spontaneously fluctuates (<a href="./references#CD000458-bbs2-0061" title="Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>). Studies on the natural history of tardive dyskinesia have reported widely variable remission rates (1% to 62%) depending on patient age, psychiatric diagnosis, course of the psychiatric disorder, and duration of therapy (<a href="./references#CD000458-bbs2-0067" title="BergenJA , EylandEA , CampbellJA . The course of tardive dyskinesia in patients on long‐term neuroleptics. British Journal of Psychiatry1989;154:523‐8. ">Bergen 1989</a>; <a href="./references#CD000458-bbs2-0087" title="FernandezHH , KruppB , FriedmanJH . The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14‐year follow‐up. Neurology2001;56:805‐7. ">Fernandez 2001</a>; <a href="./references#CD000458-bbs2-0091" title="GlazerWM , MorgensternH , SchoolerN , BerkmanCS , MooreDC . Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry1990;157(4):585‐92. ">Glazer 1990</a>). </p> <p>Although the most frequent cause of TD is the use of antipsychotic medication, it is clinically striking that dose reduction can lead to a temporary exacerbation in symptoms. Conversely, increasing the dose is often associated with a temporary remission (<a href="./references#CD000458-bbs2-0075" title="CavallaroR , RegazzettiMG , MundoE , BrancatoV , SmeraldiE . Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and persistence. Neuropsychopharmacology1993;8(3):233‐9. ">Cavallaro 1993</a>; <a href="./references#CD000458-bbs2-0119" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37:1368‐73. ">Smith 1980</a>). The exact mechanisms of the pathophysiology of TD are unknown. Antipsychotic drugs block certain chemical receptor sites in the brain — one of these is specific for dopamine (<a href="./references#CD000458-bbs2-0074" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). One hypothesis explaining the cause of antipsychotic‐induced TD is that chronic blockade of dopamine receptors in specific cells of the brain (neurones from the nigrostriatum) causes an overgrowth of these receptors (<a href="./references#CD000458-bbs2-0074" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). There is also suggestion that the chronic use of antipsychotics may also cause an abnormal production of highly active atoms and chemical groups (cytotoxic free radicals), which may damage specific cells in the brain. This, in turn, could be responsible for the appearance of TD (<a href="./references#CD000458-bbs2-0073" title="CadetJL , LohrJB . Possible involvement of free radical in neuroleptic‐induced movement disorders. Annals of the New York Academy of Sciences1989;570:176‐185. ">Cadet 1989</a>; <a href="./references#CD000458-bbs2-0115" title="SachdevP . The Current Status of Tardive Dyskinesia. Australian and New Zealand Journal of Psychiatry2000;34(3):335‐69. ">Sachdev 2000</a>). </p> <p>TD occurs in more than 20% of those using antipsychotic medication continually for longer than three months (<a href="./references#CD000458-bbs2-0092" title="GlazerWM . Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Journal of Clinical Psychiatry2000;61(suppl 4):15‐20. ">Glazer 2000</a>; <a href="./references#CD000458-bbs2-0102" title="KaneJM , SmithJM . Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry1982;39(4):473‐81. ">Kane 1982</a>; <a href="./references#CD000458-bbs2-0125" title="TarsyD , LunguC , BaldessariniRJ . Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology / Edited by P.J. Vinken and G.W. Bruyn2011;100:601‐16. ">Tarsy 2011</a>). Every year 4% to 5% of adults and 25% to 30% of elderly persons who continually use these drugs begin to show signs of TD (<a href="./references#CD000458-bbs2-0061" title="Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>; <a href="./references#CD000458-bbs2-0079" title="CorrellCU , LeuchtS , KaneJM . Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of 1‐year studies. American Journal of Psychiatry2004;161(3):414‐25. ">Correll 2004</a>). Advancing age is a risk factor for both TD's prevalence and severity, with those who are under 60 years of age being three times more likely to spontaneously remit (<a href="./references#CD000458-bbs2-0100" title="JesteDV . Tardive dyskinesia in older patients. Journal of Clinical Psychiatry2000;61(suppl 4):27‐32. ">Jeste 2000</a>; <a href="./references#CD000458-bbs2-0119" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37:1368‐73. ">Smith 1980</a>). </p> <p>The prevalence of tardive dyskinesia is often thought to be decreasing based on the use of atypical antipsychotics in place of typical antipsychotics (<a href="./references#CD000458-bbs2-0078" title="CloudLJ , ZutshiD , FactorSA . Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder. Neurotherapeutics2014;11:166‐176. ">Cloud 2014</a>). A systematic review found that the incidence of tardive dyskinesia associated with atypical drugs (2% to 4%) was significantly lower than that for typicals (5% to 8%) (<a href="./references#CD000458-bbs2-0080" title="CorrellCU , SchenkaEM . Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry2008;21:151‐6. ">Correll 2008</a>). Despite this, the widespread use of atypical drugs in clinical settings, increased off‐label use, and an ageing population may still result in an overall increase in the number of cases of TD (<a href="./references#CD000458-bbs2-0078" title="CloudLJ , ZutshiD , FactorSA . Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder. Neurotherapeutics2014;11:166‐176. ">Cloud 2014</a>; <a href="./references#CD000458-bbs2-0092" title="GlazerWM . Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Journal of Clinical Psychiatry2000;61(suppl 4):15‐20. ">Glazer 2000</a>; <a href="./references#CD000458-bbs2-0108" title="MaherAR , TheodoreG . Summary of the comparative effectiveness review on off‐label use of atypical antipsychotics. Journal of Managed Care Pharmacy2012;18(5 Suppl B):S1‐20. ">Maher 2012</a>). The problem will be considerably greater for people in countries where use of newer drugs is less prevalent (<a href="./references#CD000458-bbs2-0064" title="BallesterosJ , Gonzalez‐PintoA , BulbenaA . Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta‐analysis of seven independent studies. Journal of Clinical Psychopharmacology2000;20(2):188‐94. ">Ballesteros 2000</a>; <a href="./references#CD000458-bbs2-0110" title="MartinsES , RossoA , CoutinhoE , AdamsC , HufG . Prevalence of tardive dyskinesia and all‐cause mortality amongst patients in a large psychiatirc institute in Rio de Janeiro. Revista de Psiquiatria Clínica2011;38:44. ">Martins 2011</a>). </p> </section> <section id="CD000458-sec-0025"> <h3 class="title" id="CD000458-sec-0025">Description of the intervention</h3> <p>Catecholamines occur naturally in the body. They are synthesised from the amino acid tyrosine, and examples include epinephrine (adrenaline), norepinephrine and dopamine. There are several pharmaceutical compounds acting as catecholamine analogues that have been tested as treatment for tardive dyskinesia, especially during the 1980s (<a href="./references#CD000458-bbs2-0099" title="JesteDV , LohrJB , ClarkK , WyattRJ . Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology1988;8(4):49S. ">Jeste 1988</a>). This review will present data on pharmaceutical compounds affecting catecholamiergic pathways in different ways. </p> <p>The catecholaminergic systems involve a complex cascade of steps that can be modified by pharmaceutical compounds at various junctures. Several strategies have been examined in the treatment of TD. These include: i. increasing the presynaptic release of dopamine (e.g. amantadine); ii. increasing the production of dopamine (e.g. L‐dopa); iii. dopamine receptor antagonists (e.g. alpha‐methyl‐paratyrosine (AMTP)); iv. dopamine receptor agonists (e.g. apomorphine); v. agents that deplete dopamine (e.g. tetrabenazine); vi. agents that block the beta‐adrenergic receptors (e.g. propanolol); vii. agents that act as 'false neurotransmitters' (e.g. methyldopa) (see <a href="#CD000458-sec-0033">Types of interventions</a> for the full list of drugs). </p> </section> <section id="CD000458-sec-0026"> <h3 class="title" id="CD000458-sec-0026">How the intervention might work</h3> <p>One of the most influential theories to explain the appearance of TD suggests that long‐term use of antipsychotic medication leads to an increase in the number of dopamine and dopamine‐related receptors. This hypothesis is usually referred to as the dopamine supersensitivity theory (<a href="./references#CD000458-bbs2-0072" title="BrowneJ , SilverH , MartinR , HartR , MergenerM , WilliansP . The use of clonidine in the treatment of neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychopharmacology1986;6(2):88‐92. ">Browne 1986b</a>; <a href="./references#CD000458-bbs2-0074" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>); and hence drugs that influence the catecholaminergic (noradrenergic and dopaminergic) function in the extrapyramidal system have been used as treatments for antipsychotic‐induced TD. It was thought that these compounds could reverse dopamine supersensitivity by increasing the levels of available dopamine, thus overcoming the antipsychotic‐induced dopamine blockade (<a href="./references#CD000458-bbs2-0089" title="FriedhoffAJ . Receptor sensitivity modification (RSM): a new paradigm for the potential treatment of some hormonal and transmitter disturbances. Comprehensive Psychiatry1977;18(4):309‐17. ">Friedhoff 1977</a>). </p> <p>Currently, however, there is no clear evidence of the effectiveness of these drugs in treating TD. Nevertheless, they have been associated with many side effects, including drowsiness, confusion, postural hypotension, depression and worsening of psychosis (<a href="./references#CD000458-bbs2-0128" title="TurjanskiN , LloydGG . Psychiatric side‐effects of medications: recent developments. Advances in Psychiatric Treatment2005;11(1):58‐70. ">Turjanski 2005</a>). In addition, an excess of dopamine has itself been associated with movement disorders (choreoathetoid). </p> </section> <section id="CD000458-sec-0027"> <h3 class="title" id="CD000458-sec-0027">Why it is important to do this review</h3> <p>Several atypical antipsychotic drugs have been produced in the last decades that claim to cause less or no TD (<a href="./references#CD000458-bbs2-0107" title="LiebermanJA , FleishhackerW . Introduction. British Journal of Psychiatry1996;168(Supplement 29):7‐8. ">Lieberman 1996</a>). These claims may or may not be true, and certainly evidence does point to the fact that thoughtful use of older‐generation drugs is not associated with any more problems of TD than are newer treatments (<a href="./references#CD000458-bbs2-0077" title="ChouinardG , ChouinardVA . Atypical antipsychotics: CATIE study, drug‐induced movement disorder and resulting iatrogenic psychiatric‐like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics2008;77(2):69‐77. ">Chouinard 2008</a>). However, in a global context, it is likely that the less expensive and more familiar drugs — such as chlorpromazine or haloperidol — will continue to be the mainstay of treatment of people with schizophrenia (<a href="http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf" target="_blank">WHO Essential List 2010</a>). Use of drugs such as these is associated with emergence of TD and, therefore, this condition will remain a problem for years to come. </p> <p>TD can result in considerable social and physical disability (<a href="./references#CD000458-bbs2-0065" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Academic Press. Harcourt Brace &amp; Company, Publishers, 1993. ">Barnes 1993</a>); and symptoms are often irreversible (<a href="./references#CD000458-bbs2-0067" title="BergenJA , EylandEA , CampbellJA . The course of tardive dyskinesia in patients on long‐term neuroleptics. British Journal of Psychiatry1989;154:523‐8. ">Bergen 1989</a>; <a href="./references#CD000458-bbs2-0087" title="FernandezHH , KruppB , FriedmanJH . The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14‐year follow‐up. Neurology2001;56:805‐7. ">Fernandez 2001</a>; <a href="./references#CD000458-bbs2-0091" title="GlazerWM , MorgensternH , SchoolerN , BerkmanCS , MooreDC . Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry1990;157(4):585‐92. ">Glazer 1990</a>). Additionally, TD is frequently associated with lower quality of life (<a href="./references#CD000458-bbs2-0063" title="Ascher‐SvanumH , ZhuB , FariesD , PengX , KinonBJ , TohenM . Tardive dyskinesia and the 3‐year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry2008;69(10):1580‐8. ">Ascher‐Svanum 2008</a>); and a greater mortality rate (<a href="./references#CD000458-bbs2-0076" title="ChongSA , TayJA , SubramaniamM , PekE , MachinD . Mortality rates among patients with schizophrenia and tardive dyskinesia. Journal of Clinical Psychopharmacology2009;29:5‐8. ">Chong 2009</a>). Given the high incidence and prevalence of TD among people taking antipsychotic medication, the need for prevention or treatment is clear. Unfortunately, there has been sparse evidence to guide clinicians (<a href="./references#CD000458-bbs2-0112" title="NICE . Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 (guidance.nice.org.uk/cg178)2014. ">NICE 2014</a>; <a href="./references#CD000458-bbs2-0126" title="TaylorD , PatonC , KapurS . The Maudsley Prescribing Guidelines (10th Edition). London: Informa Healthcare, 2009. ">Taylor 2009</a>). Although many treatments have been tested, no one intervention has been shown clearly to be effective. Cessation or reduction of the dose of antipsychotic medication would be the ideal management for TD. In clinical practice this is not always possible, not least because in many individuals such a reduction would lead to relapse. This review focuses on whether the addition of different types of catecholaminergic medications to those already receiving antipsychotic medication is likely to help TD. </p> <p>This review is one in a series of Cochrane Reviews evaluating treatments for antipsychotic‐induced TD (see <a href="#CD000458-tbl-0005">Table 1</a>), and is an update of a Cochrane Review first published in 2006 (<a href="./references#CD000458-bbs2-0131" title="El‐SayehHG , Lyra da SilvaJP , RathboneJ , Soares‐WeiserK . Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2] ">El‐Sayeh 2006</a>). </p> <div class="table" id="CD000458-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0120" title="Soares‐WeiserK , MobsyC , HollidayE . Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews1997, Issue 2. [DOI: 10.1002/14651858.CD000204] ">Soares‐Weiser 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0069" title="BhoopathiPS , Soares‐WeiserK . Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2] ">Bhoopathi 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0086" title="EssaliA , DeirawanH , Soares‐WeiserK , AdamsCE . Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3] ">Essali 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0124" title="TammenmaaI , McGrathJ , SailasE , Soares‐WeiserK . Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD000207] ">Tammenmaa 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐aminobutyric acid agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0059" title="AlabedS , LatifehY , MohammadHA , RifaiA . Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3] ">Alabed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0121" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroleptic reduction and/or cessation and neuroleptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0122" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐neuroleptic catecholaminergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0123" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000458-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000458-sec-0028"></div> <p>1. To determine the effects of any of the following drugs for antipsychotic‐induced TD in people with schizophrenia or other chronic mental illnesses.<br/> i. Drugs which influence the noradrenergic system.<br/> ii. Dopamine receptor agonists.<br/> iii. Dopamine receptor antagonists.<br/> iv. Dopamine‐depletor drugs.<br/> v. Drugs that increase the production or release of dopamine. </p> <p>2. To examine whether any improvement occurred with short periods of intervention (less than 6 weeks) and, if this did occur, whether this effect was maintained at longer periods of follow‐up. </p> <p>3. To examine if there was a differential effect for the various compounds.</p> <p>4. To examine whether the use of non‐antipsychotic catecholaminergic drugs are most effective in those with more recent onset TD (less than five years). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000458-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000458-sec-0029"></div> <section id="CD000458-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000458-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials. Where a trial was described as 'double‐blind' but it was implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <a href="#CD000458-sec-0036">Types of outcome measures</a>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi‐randomised studies, such as those allocating by using alternate days of the week. </p> </section> <section id="CD000458-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia or any other chronic mental illness, diagnosed by any criteria, irrespective of gender, age or nationality who:<br/> i. required the use of antipsychotics for more than three months;<br/> ii. developed tardive dyskinesia (diagnosed by any criteria) during antipsychotic treatment; and<br/> iii. for whom the dose of antipsychotic medication had been stable for one month or more before the trial (the same applies for those free of antipsychotics). </p> </section> <section id="CD000458-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD000458-sec-0034"> <h5 class="title">A. Noradrenergic drugs</h5> <p>i. Celiprolol, clonidine, disulfiram, fusaric acid, methyldopa, pindolol, propanolol, oxprenolol or yohimbine, compared with placebo or no intervention. For the 2017 update a post hoc decision was made to also include studies evaluating the above‐mentioned noradrenergic drugs compared to any other intervention for the treatment of tardive dyskinesia. </p> </section> <section id="CD000458-sec-0035"> <h5 class="title">B. Dopaminergic drugs</h5> <p>i. The dopamine receptor agonists (apomorphine, bromocriptine, CF25‐397, dopamine, hydergine, lisuride);<br/> ii. the dopamine receptor antagonists (AMTP, oxiperomide, metoclopramide, papaverine, tiapride);<br/> iii. the dopamine‐depleting drugs (oxypertine, reserpine, tetrabenazine);<br/> iv. drugs that increase the release (amantadine, amphetamine) or production (L‐dopa) of dopamine;<br/> all compared with placebo or no intervention. For the 2017 update a post hoc decision was made to also include studies evaluating the above mentioned dopaminergic drugs compared to any other intervention for the treatment of tardive dyskinesia. </p> </section> </section> <section id="CD000458-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We have defined clinical efficacy as an improvement in the symptoms of TD of more than 50%, on any scale. We grouped outcomes into short term (less than six weeks), medium term (between six weeks and six months) and long term (more than six months). </p> <section id="CD000458-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD000458-sec-0038"> <h6 class="title">1. Tardive dyskinesia</h6> <p>No clinically important improvement in the symptoms of individuals, defined as more than 50% improvement on any tardive dyskinesia scale ‒ any time period. </p> </section> <section id="CD000458-sec-0039"> <h6 class="title">2. Adverse effects</h6> <p>No clinically significant extrapyramidal adverse effects ‒ any time period.</p> </section> </section> <section id="CD000458-sec-0040"> <h5 class="title">Secondary outcomes</h5> <section id="CD000458-sec-0041"> <h6 class="title">1. Tardive dyskinesia (TD)</h6> <p>1.1 Any improvement in the symptoms of individuals on any TD scale, as opposed to no improvement.<br/> 1.2 Deterioration in the symptoms of individuals, defined as any deleterious change on any TD scale.<br/> 1.3 Average change in severity of TD during the trial period.<br/> 1.4 Average difference in severity of TD at the end of the trial. </p> </section> <section id="CD000458-sec-0042"> <h6 class="title">2. General mental state changes</h6> <p>2.1 Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any scale.<br/> 2.2 Average difference in severity of psychiatric symptoms at the end of the trial. </p> </section> <section id="CD000458-sec-0043"> <h6 class="title">3. Acceptability of the treatment</h6> <p>3.1 Acceptability of the intervention to the participant group as measured by numbers of people dropping out during the trial. </p> </section> <section id="CD000458-sec-0044"> <h6 class="title">4. Adverse effects</h6> <p>4.1 Use of any anti‐parkinsonism drugs.<br/> 4.2 Average score/change in extrapyramidal adverse effects.<br/> 4.3 Acute dystonia. </p> </section> <section id="CD000458-sec-0045"> <h6 class="title">5. Other adverse effects, general and specific</h6> </section> <section id="CD000458-sec-0046"> <h6 class="title">6. Hospital and service utilisation outcomes</h6> <p>6.1 Hospital admission.<br/> 6.2 Average change in days in hospital.<br/> 6.3 Improvement in hospital status (for example: change from formal to informal admission status, use of seclusion, level of observation). </p> </section> <section id="CD000458-sec-0047"> <h6 class="title">7. Economic outcomes</h6> <p>7.1 Average change in total cost of medical and mental health care.<br/> 7.2 Total indirect and direct costs. </p> </section> <section id="CD000458-sec-0048"> <h6 class="title">8. Social confidence, social inclusion, social networks, or personalised quality of life measures </h6> <p>8.1. No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures.<br/> 8.2 Average score/change in social confidence, social inclusion, social networks, or personalised quality of life measures. </p> </section> <section id="CD000458-sec-0049"> <h6 class="title">9. Behaviour</h6> <p>9.1 Clinically significant agitation.<br/> 9.2 Use of adjunctive medication for sedation.<br/> 9.3 Aggression to self or others. </p> </section> <section id="CD000458-sec-0050"> <h6 class="title">10. Cognitive state</h6> <p>10.1 No clinically important change.<br/> 10.2 No change, general and specific. </p> </section> <section id="CD000458-sec-0051"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD000458-bbs2-0118" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>) and used <a href="http://methods.cochrane.org/gradeing/gradepro-gdt" target="_blank">GRADEpro</a> to export data from this review to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effects of interventions examined and the sum of available data on all outcomes rated as important to patient care and decision making. This summary was used to guide our conclusions. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p><b>1. Tardive dyskinesia</b><br/> 1.1 Improved to a clinically important extent<br/> 1.2 Deteriorated </p> <p><b>2. Mental state</b><br/> 2.1 Deteriorated </p> <p><b>3. Adverse effect</b><br/> 3.1 Any adverse event<br/> 3.2 Adverse effects: no clinically significant extrapyramidal adverse effects </p> <p><b>4. Acceptability of treatment</b><br/> 4.1 Leaving the study early </p> <p><b>5. Social confidence, social inclusion, social networks, or personalised quality of life measures</b>*<br/> 5.1 No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures for either recipients of care or caregivers </p> <p>* Outcome designated important to patients. We wished to add perspectives from people’s personal experience with TD to the research agenda. A consultation with service users was planned where the previously published version of another review in the tardive dyskinesia series and a lay overview of that review gave the foundation for the discussions (<a href="./references#CD000458-bbs2-0123" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a>; <a href="#CD000458-tbl-0005">Table 1</a>). The session was planned to provide time to reflect on current research on TD and consider gaps in knowledge. The report is published in the Health Technology Assessment (HTA) report for the UK National Institute of Health Research (<a href="./appendices#CD000458-sec-0232">Appendix 1</a>, <a href="./references#CD000458-bbs2-0068" title="BergmanH , WalkerDM , NikolakopoulouA , Soares‐WeiserK , AdamsCE . Systematic review of interventions for treating or preventing antipsychotic‐induced tardive dyskinesia. Health Technol Assess2017 Aug;21(43):1‐218. ">Bergman 2017</a>). We have added one figure showing a service user's expression of frustration concerning this neglected area of research (<a href="#CD000458-fig-0001">Figure 1</a>). Informed by the results of the consultation, for this review we updated outcomes for the 'Summary of findings' table. </p> <div class="figure" id="CD000458-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research." data-id="CD000458-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research. </p> </div> </div> </div> </section> </section> </section> </section> <section id="CD000458-sec-0052"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000458-sec-0053"> <h4 class="title">Electronic searches</h4> <p>The 2017 review update was carried out in parallel with updating eight other TD reviews; see <a href="#CD000458-tbl-0005">Table 1</a> for details. The search covered all nine tardive dyskinesia reviews. </p> <section id="CD000458-sec-0054"> <h5 class="title">1. Cochrane Schizophrenia Group’s Register</h5> <p>We searched Cochrane Schizophrenia Group’s Study‐Based Register of Trials on 16 July 2015 and 26 April 2017 using the following string: <i>*Tardive Dyskinesia* in Healthcare Condition Field of Study.</i> In a study‐based register such as this, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. The Cochrane Schizophrenia Group’s Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> <section id="CD000458-sec-0055"> <h5 class="title">3. Details of previous electronic searches</h5> <p>See <a href="./appendices#CD000458-sec-0232">Appendix 1</a>. </p> </section> </section> <section id="CD000458-sec-0056"> <h4 class="title">Searching other resources</h4> <section id="CD000458-sec-0057"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all identified studies for further relevant studies.</p> </section> <section id="CD000458-sec-0058"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD000458-sec-0059"> <h3 class="title" id="CD000458-sec-0059">Data collection and analysis</h3> <section id="CD000458-sec-0060"> <h4 class="title">Selection of studies</h4> <p>For the 2017 update, reviewers RA and AG (see <a href="#CD000458-sec-0229">Acknowledgements</a>) inspected all abstracts of studies identified as above and identified potentially relevant reports. We resolved disagreement by discussion, or where there was still doubt, we acquired the full article for further inspection. We acquired the full articles of relevant reports/abstracts meeting initial criteria for reassessment and carefully inspected for a final decision on inclusion (see <a href="#CD000458-sec-0030">Criteria for considering studies for this review</a>). RA and AG were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked author HB for help and where it was impossible to decide or if adequate information was not available to make a decision, we added these studies to those awaiting assessment and contacted the authors of the papers for clarification. </p> </section> <section id="CD000458-sec-0061"> <h4 class="title">Data extraction and management</h4> <section id="CD000458-sec-0062"> <h5 class="title">1. Extraction</h5> <p>For the 2017 update, reviewers RA and HB independently extracted data from all included studies. Again, we discussed any disagreement and documented decisions. With remaining problems KSW helped clarify issues and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but included only if two reviewers independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi‐centre, where possible we extracted data relevant to each component centre separately. </p> </section> <section id="CD000458-sec-0063"> <h5 class="title">2. Management</h5> <section id="CD000458-sec-0064"> <h6 class="title">2.1 Forms</h6> <p>For the 2017 update we extracted data online in <a href="https://www.covidence.org" target="_blank">Covidence</a>. Extracted data are available <a href="https://www.researchgate.net/publication/308698005_Appendix_Traceable_Extracted_Data_from_Included_Studies_of_Tardive_Dyskinesia_Reviews?channel=doi%26linkId=57ebe1c508ae92a5dbd051c1%26showFulltext=true" target="_blank">here</a> with a link to the original source PDF for each item. </p> </section> <section id="CD000458-sec-0065"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> <br/> a) the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD000458-bbs2-0109" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument has not been written or modified by one of the trialists for that particular trial.<br/> <br/> Ideally the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we noted in <a href="#CD000458-sec-0106">Description of studies</a> if this was the case or not. </p> </section> <section id="CD000458-sec-0066"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). </p> </section> <section id="CD000458-sec-0067"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant data before inclusion (see (a), (b) and (c) below). </p> <p>Please note: we entered data from studies of at least 200 participants in the analysis, because skewed data pose less of a problem in large studies. We also entered all relevant change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. </p> <p>For endpoint data from studies with fewer than 200 participants:</p> <p>(a) when a scale starts from the ﬁnite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we excluded these data. If this ratio was higher than 1 but below 2, there is suggestion of skew. We entered these data and tested whether their inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2 we included these data, because skew is less likely (<a href="./references#CD000458-bbs2-0060" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). </p> <p>(b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (<a href="./references#CD000458-bbs2-0103" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S − S min), where S is the mean score and 'S min' is the minimum score. </p> </section> <section id="CD000458-sec-0068"> <h6 class="title">2.5 Common measure</h6> <p>Where relevant, to facilitate comparison between trials we converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD000458-sec-0069"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we converted continuous outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD000458-bbs2-0113" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD000458-bbs2-0103" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this can be considered as a clinically significant response (<a href="./references#CD000458-bbs2-0105" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>; <a href="./references#CD000458-bbs2-0106" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> </section> </section> <section id="CD000458-sec-0070"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Reviewers RA (see <a href="#CD000458-sec-0229">Acknowledgements</a>) and HB independently assessed risk of bias within the included studies by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non‐concurrence occurred, we reported this. </p> <p>We noted the level of risk of bias in the text of the review and in <a href="#CD000458-fig-0002">Figure 2</a>, <a href="#CD000458-fig-0003">Figure 3</a>, <a href="./full#CD000458-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD000458-tbl-0003">summary of findings Table 3</a>. </p> <div class="figure" id="CD000458-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000458-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD000458-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000458-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD000458-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <section id="CD000458-sec-0072"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (<a href="./references#CD000458-bbs2-0071" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>), as odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD000458-bbs2-0081" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). </p> </section> <section id="CD000458-sec-0073"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there is a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD000458-sec-0074"> <h4 class="title">Unit of analysis issues</h4> <section id="CD000458-sec-0075"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated (<a href="./references#CD000458-bbs2-0082" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>). This causes type I errors (<a href="./references#CD000458-bbs2-0070" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD000458-bbs2-0093" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If any of the included trials had randomised participants by clusters, and where clustering is not accounted for in primary studies, we would have presented such data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD000458-bbs2-0093" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra‐class correlation coefficient (ICC) (Design effect = 1 + (m − 1) * ICC] (<a href="./references#CD000458-bbs2-0083" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21(19):2971‐80. ">Donner 2002</a>)). If the ICC is not reported it will be assumed to be 0.1 (<a href="./references#CD000458-bbs2-0129" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account intra‐class correlation coefficients and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD000458-sec-0076"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD000458-bbs2-0085" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD000458-sec-0077"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant we presented the additional treatment arms in comparisons. If data were binary we simply added and combined within the two‐by‐two table. If data were continuous we combined data following the formula in section 7.7.3.8  (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>)<i>.</i> We did not use data where the additional treatment arms were not relevant. </p> </section> </section> <section id="CD000458-sec-0078"> <h4 class="title">Dealing with missing data</h4> <section id="CD000458-sec-0079"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss to follow‐up, data must lose credibility (<a href="./references#CD000458-bbs2-0130" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table/s by down‐rating quality. We also downgraded quality within the 'Summary of findings' table/s should loss be 25% to 50% in total. </p> </section> <section id="CD000458-sec-0080"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome is between 0% and 50% and where these data are not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). We assumed all those leaving the study early had no improvement. We undertook a sensitivity analysis testing how prone the primary outcomes were to change by comparing data only from people who completed the study to that point to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD000458-sec-0081"> <h5 class="title">3. Continuous</h5> <section id="CD000458-sec-0082"> <h6 class="title">3.1 Attrition</h6> <p>We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported. </p> </section> <section id="CD000458-sec-0083"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or t value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>): when only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * √(n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> present detailed formulae for estimating SDs from P, t or F values, confidence intervals, ranges or other statistics (<a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD000458-bbs2-0090" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD000458-sec-0084"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers; others use the method of last observation carried forward (LOCF); while more recently, methods such as 'multiple imputation' or 'mixed effects' models for repeated measurements (MMRM) have become more of a standard. While the last two methods seem to be somewhat better than LOCF (<a href="./references#CD000458-bbs2-0104" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies which used the statistical approach. However, we preferred to use the more sophisticated approaches (e.g. MMRM or 'multiple imputation') and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'Incomplete outcome data' of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD000458-sec-0085"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD000458-sec-0086"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise; and discussed in the text if they arose. </p> </section> <section id="CD000458-sec-0087"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise; and discussed in the text if they arose. </p> </section> <section id="CD000458-sec-0088"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD000458-sec-0089"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD000458-sec-0090"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD000458-bbs2-0096" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed value of I² depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi² test, or a confidence interval for I²). An I² estimate greater than or equal to around 50% accompanied by a statistically significant Chi² statistic can be interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 <i>Cochrane Handbook for Systematic Reviews of Interventions;</i><a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (<a href="#CD000458-sec-0093">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD000458-sec-0091"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD000458-bbs2-0084" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000458-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there are 10 or fewer studies, or where all studies were of similar sizes. If funnel plots are possible in future versions of this review, we will seek statistical advice in their interpretation. </p> </section> <section id="CD000458-sec-0092"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for fixed‐effect over random‐effects models, or vice versa. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. </p> </section> <section id="CD000458-sec-0093"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD000458-sec-0094"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD000458-sec-0095"> <h6 class="title">1.1 Type of compound</h6> <p>As different non‐antipsychotic catecholaminergic compounds may have differential effects on antipsychotic‐induced tardive dyskinesia, we performed a subgroup analysis to compare the effects of different non‐antipsychotic catecholaminergic drugs. We proposed to undertake comparisons only for primary outcomes to minimise the risk of multiple comparisons. </p> </section> <section id="CD000458-sec-0096"> <h6 class="title">1.2 Duration of treatment</h6> <p>We also anticipated a sub‐group analysis to examine whether any improvement occurred with short periods of intervention (less than six weeks); and if this did occur, whether this effect was maintained at longer periods of follow‐up. </p> </section> <section id="CD000458-sec-0097"> <h6 class="title">1.3 Clinical state, stage or problem: recent onset TD</h6> <p>We proposed to undertake this review and provide an overview of the effects of non‐antipsychotic catecholaminergic drugs for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. We anticipated testing the hypothesis that the use of non‐antipsychotic catecholaminergic drugs is most effective for those with more recent onset TD (less than five years). We had hoped to present data for this subgroup for the primary outcomes. </p> </section> </section> <section id="CD000458-sec-0098"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We reported when inconsistency was high. First we investigated whether data were entered correctly. Second, if data were correct, we visually inspected the graph and successively removed studies from the rest to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, we did not pool such data and discussed issues. We know of no supporting research for this 10% cut‐off but we are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply discussed. We did not undertake sensitivity analyses relating to these. </p> </section> </section> <section id="CD000458-sec-0099"> <h4 class="title">Sensitivity analysis</h4> <section id="CD000458-sec-0100"> <h5 class="title">1. Implication of randomisation</h5> <p>If trials were described in some way as to imply randomisation we undertook sensitivity analyses for the primary outcomes. We included these studies in the analyses and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we used relevant data from these studies. </p> </section> <section id="CD000458-sec-0101"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD000458-sec-0078">Dealing with missing data</a>) we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> <p>Where assumptions have to be made regarding missing SDs data (see <a href="#CD000458-sec-0078">Dealing with missing data</a>), we compared the findings on primary outcomes when we used our assumption with completer data only. We undertook a sensitivity analysis, testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> </section> <section id="CD000458-sec-0102"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis. </p> </section> <section id="CD000458-sec-0103"> <h5 class="title">4. Imputed values</h5> <p>Had cluster trials been included, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect. </p> <p>If we found substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately </p> </section> <section id="CD000458-sec-0104"> <h5 class="title">5. Fixed and random effects</h5> <p>We synthesised data using a fixed‐effect model; however, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000458-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000458-sec-0105"></div> <section id="CD000458-sec-0106"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD000458-sec-0250" title="">Characteristics of included studies</a>, <a href="./references#CD000458-sec-0251" title="">Characteristics of excluded studies</a> and Characteristics of studies awaiting classification. </p> <section id="CD000458-sec-0107"> <h4 class="title">Results of the search</h4> <p>The 2015 and 2017 update searches were part of an update search of nine Cochrane Reviews; see <a href="#CD000458-tbl-0005">Table 1</a>. The 2015 search retrieved 704 references for 344 studies; see <a href="#CD000458-fig-0004">Figure 4</a> for study flow diagram. After having excluded irrelevant references at title and abstract screening, we screened full texts of 71 references (58 studies). Forty‐eight studies (57 references) were excluded, and 29 of these are new excluded studies for the 2017 update. Two studies were awaiting assessment in the previous version of the review and have since been assessed in Chinese and Portuguese, found to have met inclusion criteria, and included (<a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>). Another six new studies were included from the 2015 search (<a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>; <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). Ten studies are now included in this review. </p> <div class="figure" id="CD000458-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Study flow diagram for 2015 and 2017 searching" data-id="CD000458-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for 2015 and 2017 searching</p> </div> </div> </div> <p>The 2017 search found eight records (five studies). The Editorial base of Cochrane Schizophrenia screened these records and no new studies were relevant to this review. They could be relevant to the other reviews in this series of TD reviews (see <a href="#CD000458-tbl-0005">Table 1</a>), and have been put into 'Studies awaiting classification' of the <a href="./references#CD000458-bbs2-0122" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a> miscellaneous treatments review. </p> </section> <section id="CD000458-sec-0108"> <h4 class="title">Included studies</h4> <p>Overall the review now includes 10 studies with 261 participants published between 1973 and 2010. Eight of these studies were added at the 2017 update (<a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>; <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). </p> <section id="CD000458-sec-0109"> <h5 class="title">1. Methods</h5> <p>All studies were stated to be randomised and double blind. For further details, please see sections below on <a href="#CD000458-sec-0137">Allocation (selection bias)</a> and <a href="#CD000458-sec-0138">Blinding (performance bias and detection bias)</a>. </p> </section> <section id="CD000458-sec-0110"> <h5 class="title">2. Design</h5> <p>All included studies presented a parallel longitudinal design. Three of the 10 studies used a cross‐over design with two periods (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>; <a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>). We had considered this possibility when embarking on the review and have used only the data from before the first cross‐over for the reasons outlined above (see <a href="#CD000458-sec-0074">Unit of analysis issues</a>). </p> </section> <section id="CD000458-sec-0111"> <h5 class="title">3. Duration</h5> <p>Treatment phases of five studies were of short duration (2 to 5 weeks) (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>; <a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>); and treatment phases of the remaining five studies were of medium duration (6 to 24 weeks) (<a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>; <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). </p> </section> <section id="CD000458-sec-0112"> <h5 class="title">4. Participants</h5> <p>Participants, now totalling 261 people, were mostly men in their 50s, with diagnoses of various chronic psychiatric disorders, but mainly schizophrenia. All had antipsychotic‐induced tardive dyskinesia (TD), though only four studies reported the specific diagnostic criteria used (<a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>; <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). The number of participants ranged from 12 to 50 (median 21). </p> </section> <section id="CD000458-sec-0113"> <h5 class="title">5. Setting</h5> <p>One trial was conducted with outpatients in Greece (<a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>); and the rest with psychiatric inpatients in the USA (<a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>), Austria (<a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>), Brazil (<a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>), China (<a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>), France (<a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>), the Netherlands (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>), and the UK (<a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). </p> </section> <section id="CD000458-sec-0114"> <h5 class="title">6. Interventions</h5> <section id="CD000458-sec-0115"> <h6 class="title">6.1 Noradrenergic drugs</h6> <section id="CD000458-sec-0116"> <p><b>6.1.1 Alpha‐methyldopa</b></p> <p><a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a> used alpha‐methyldopa in a dose ranging from 750 to 1500 mg/day. Methyldopa inhibits dopamine production and is also an adrenergic receptor agonist, and is used to treat hypertension and pregnancy‐induced hypertension. </p> </section> <section id="CD000458-sec-0117"> <p><b>6.1.2 Celiprolol</b></p> <p><a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a> used celiprolol in a 200 mg/day dose. Celiprolol is a cardioselective beta blocker reported to possess intrinsic sympathomimetic activity and direct vasodilator activity. Celiprolol is used as the hydrochloride in the management of hypertension and angina pectoris. </p> </section> </section> <section id="CD000458-sec-0118"> <h6 class="title">6.2 Dopaminergic drugs</h6> <section id="CD000458-sec-0119"> <p><b>6.2.1 Amantadine</b></p> <p><a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a> used amantadine in a dose of 100 mg/day. Amantadine is a glutamate receptor antagonist and anticholinergic that increases dopamine release and blocks dopamine reuptake. It can be used both as an antiviral and antiparkinsonian drug. </p> </section> <section id="CD000458-sec-0120"> <p><b>6.2.2 Bromocriptine</b></p> <p><a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a> used bromocriptine one capsule twice per day (exact dose unknown). Bromocriptine is a dopamine agonist used to treat various conditions including pituitary tumours, Parkinson's disease, type 2 diabetes, and cocaine withdrawal. </p> </section> <section id="CD000458-sec-0121"> <p><b>6.2.3 Carbidopa/levodopa (L‐dopa)</b></p> <p><a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a> used carbidopa/levodopa in a dose of 50/350 mg/day. <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a> used levodopa in a dose ranging from 500 mg to 2000 mg. Carbidopa is used in Parkinson's disease in combination with levodopa to make levodopa more accessible. L‐dopa is the precursor to the catecholaminergic neurotransmitters dopamine, noradrenaline and adrenaline. L‐dopa can also be manufactured and is used as a drug to treat Parkinson's disease. </p> </section> <section id="CD000458-sec-0122"> <p><b>6.2.4 Oxypertine</b></p> <p><a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a> used oxypertine in a dose ranging from 80 mg/day to 240 mg/day. Oxypertine is a dopamine depleter drug used in the treatment of mania, disturbed behaviour, psychosis and schizophrenia. </p> </section> <section id="CD000458-sec-0123"> <p><b>6.2.5 Reserpine</b></p> <p><a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a> used reserpine in a dose ranging from 0.75 to 1.5 mg/day. Reserpine is a dopamine depleter drug that has been used in the past to treat psychosis and hypertension. Today it is mainly used as a horse tranquilliser. </p> </section> <section id="CD000458-sec-0124"> <p><b>6.2.6 Tetrabenazine</b></p> <p><a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a> used tetrabenazine in a dose ranging from 50 mg to 200 mg/day. Tetrabenazine is a dopamine depleter drug approved to treat symptoms of Huntington's disease chorea. </p> </section> <section id="CD000458-sec-0125"> <p><b>6.2.7 Tiapride</b></p> <p>Two studies used tiapride in a dose ranging from 300 mg to 600 mg/day (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>). Tiapride is a substituted benzamide with general properties similar to those of the antipsychotic sulpiride. It is usually given as the hydrochloride in the management of behavioural disorders and to treat dyskinesias. Tiapride has been tried in the treatment of Tourette's syndrome and chorea such as Huntington's chorea. </p> </section> </section> <section id="CD000458-sec-0126"> <h6 class="title">6.3 Comparison group</h6> <p>In most of the studies a placebo was used as a comparison group, with no further details given. In one study the comparison group was haloperidol (<a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>). Another trial compared groups with different doses of L‐dopa and placebo (<a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>); and <a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a> included three arms: celiprolol (noradrenergic), reserpine (dopamine depleter) and placebo. </p> <p>Participants remained on stable schizophrenia treatment antipsychotic medication during the trials. </p> </section> </section> <section id="CD000458-sec-0127"> <h5 class="title">7. Outcomes</h5> <section id="CD000458-sec-0128"> <h6 class="title">7.1 General</h6> <p>Some outcomes were presented in graphs, inexact P values of differences, or a statement of significant or non‐significant difference. This made it impossible to acquire raw data for synthesis. Some continuous outcomes could not be extracted due to missing number of participants or missing means, standard deviations, or standard errors. </p> </section> <section id="CD000458-sec-0129"> <h6 class="title">7.2 Scales used to measure TD symptoms</h6> <p>We have shown details of the scales that provided usable data below. We have provided reasons for exclusions of data under 'Outcomes' in the <a href="./references#CD000458-sec-0250" title="">Characteristics of included studies</a> table. </p> <section id="CD000458-sec-0130"> <p><b>7.2.1 Abnormal Involuntary Movement Scale (AIMS)</b></p> <p><a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a> reported using AIMS to assess TD symptoms, and <a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a> reported using SKAUB, the German version of AIMS. The AIMS is a 12‐item scale consisting of a standardised examination followed by questions rating the orofacial, extremity and trunk movements, as well as three global measurements (<a href="./references#CD000458-bbs2-0095" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: Department of Health, Education and Welfare, 1976. ">Guy 1976</a>). Each of these 10 items can be scored from 0 (none) to 4 (severe). Two additional items assess dental status. The AIMS ranges from 0 to 40, with higher scores indicating greater severity. </p> </section> <section id="CD000458-sec-0131"> <p><b>7.2.2 Extrapyramidal Bilan scale (EBS)</b></p> <p><a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a> used the EBS. The EBS is a nine‐item rating scale for use by neurologists, to measure severity of symptoms such as facial mask, tremor, rigidity, akathisia, dystonia, dyskinesia and others (<a href="./references#CD000458-bbs2-0127" title="TetreaultL , BordeleauJM , AlbertJM , RajotteP . Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal1969;14(2):191‐8. ">Tetreault 1969</a>). Each item can be scored from 0 to 3, such that the overall score can range from 0 (no symptoms) to a possible 27 (severe symptoms of all types). </p> </section> <section id="CD000458-sec-0132"> <p><b>7.2.3 Clinical assessment</b></p> <p>Two studies reported using a frequency count of mouth movements, performed by a psychiatrist, to assess oral dyskinesia (<a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>). </p> </section> </section> </section> </section> <section id="CD000458-sec-0133"> <h4 class="title">Excluded studies</h4> <p>There are 48 excluded studies (57 references). Thirteen studies were not randomised and we therefore excluded them (<a href="./references#CD000458-bbs2-0014" title="AsherS , AminoffMJ . Tetrabenazine and movement disorders. Neurology1981;31(8):1051‐4. [MEDLINE: 81271166] ">Asher 1981</a>; <a href="./references#CD000458-bbs2-0020" title="ChouzaC , RomeroS , LorenzoJ , CamanoJL , FontanaAP , AlterwainP , et al. Clinical trial of tiapride in patients with dyskinesia. Semaine des Hopitaux1982;58:725‐33. ">Chouza 1982</a>; <a href="./references#CD000458-bbs2-0022" title="DelwaideP , HurletA . Bromocriptine and Buccolinguofacial Dyskinesias in Patients With Senile Dementia. Archives of Neurology1980;37(7):441‐3. ">Delwaide 1980</a>; <a href="./references#CD000458-bbs2-0026" title="FahnS . Long term treatment of tardive dyskinesia with presynaptically acting dopamine‐depleting agents. In: FahnS , CalneDB , ShoalsonI editor(s). Advances in Neurology: Experimental Therapeutics of Movement Disorders. New York: Raven Press, 1983:267‐76. ">Fahn 1983</a>; <a href="./references#CD000458-bbs2-0028" title="FerrariP , RobottiE , NardiniM . Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs [Disegno sperimentale di uno studio pilota sull'amantadina nella sindrome extrapiramidale da farmaci neurolettici]. Bollettino Chimico Farmaceutico1972;111(10):610‐5. [MEDLINE: 73069847] ">Ferrari 1972</a>; <a href="./references#CD000458-bbs2-0031" title="GerlachJ . The relationship betwen parkisonism and tardive dyskinesia. American Journal of Psychiatry1977;134(7):781‐4. GerlachJ , ThorsenK . The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Internal Pharmacopsychiatry1976;11(1):1‐7. ">Gerlach 1976</a>; <a href="./references#CD000458-bbs2-0040" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine‐depleting agent, tetrabenazine. Archives of General Psychiatry1972;27(1):95‐9. ">Kazamatsuri 1972</a>; <a href="./references#CD000458-bbs2-0041" title="KonigP , ChwatalK , HavelecL , RiedlF , SchubertH , SchultesH . Amantadine versus biperiden ‐ a double‐blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology1996;33(2):80‐4. [MEDLINE: 8927233] ">Konig 1996</a>; <a href="./references#CD000458-bbs2-0042" title="LeblhuberF . Treatment of permanent tardive dyskinesia with tiapride, a selective D2‐receptor blocking agent. Clinical Neuropharmacology1987;10(5):458‐61. ">Leblhuber 1987</a>; <a href="./references#CD000458-bbs2-0043" title="LevyMI , DavisBM , MohsRC , KendlerKS , MatheAA , TrigosG , et al. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Archives of General Psychiatry1984;41(5):520‐4. ">Levy 1984</a>; <a href="./references#CD000458-bbs2-0052" title="RingwaldE . Dopamine‐receptor stimulators and neuroleptic‐induced dyskinesia (author's transl). Pharmakopsychiatrie und Neuropsychopharmakologie1978;11:294‐8. ">Ringwald 1978</a>; <a href="./references#CD000458-bbs2-0053" title="RondotP , BathienN . Movement disorders in patients with coexistent neuroleptic‐induced tremor and tardive dyskinesia: EMG and pharmacological study. Advances in Neurology1987;45:361‐6. [MEDLINE: 87152665; PMID 2881446] ">Rondot 1987</a>; <a href="./references#CD000458-bbs2-0055" title="SmithRC , TammingaCA , HarasztiJ , PandeyGN , DavisJM . Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry1977;134(7):763‐8. ">Smith 1977</a>). Seven RCTs did not meet inclusion criteria because they recruited participants without tardive dyskinesia (<a href="./references#CD000458-bbs2-0011" title="AdlerLA , AngristB , RotrosenJ . Metoprolol versus propranolol. Biological Psychiatry1990;27(6):673‐5. [MEDLINE: 90212774; PMID 1969753] ">Adler 1990</a>; <a href="./references#CD000458-bbs2-0024" title="DiMascioA , BernardoDL , GreenblattDJ , MarderJE . A controlled trial of amantadine in drug‐induced extrapyramidal disorders. Archives of General Psychiatry1976;33(5):599‐602. [MEDLINE: 76183605] DiMascioA , BernardoDL , GreenblattDJ , MarderJE . A controlled trial of amantadine in drug‐induced extrapyramidal disorders. Psychopharmacology Bulletin1977;13(3):31‐3. ">DiMascio 1976</a>; <a href="./references#CD000458-bbs2-0027" title="FannWE , LakeCR . Amantadine versus trihexyphenidyl in the treatment of neuroleptic‐induced parkinsonism. American Journal of Psychiatry1976;133(8):940‐3. ">Fann 1976</a>; <a href="./references#CD000458-bbs2-0036" title="GutierrezM , AlpertM , GuimonJ , FriedhoffAJ , VeramendiV . Controlled study on the possibilities of L‐dopa in the residual extrapyramidal syndrome caused by neuroleptics [Un estudio controlado sobre las posibilidades de la L‐dopa en el sindrome extrapiramidal residual producido por los neurolepticos]. Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines1979;7(3):181‐8. [MEDLINE: 86065776] ">Gutierrez 1979</a>; <a href="./references#CD000458-bbs2-0048" title="NCT00310661 . A dual‐centre, double‐blind, randomized, placebo‐controlled, parallel‐group study to determine the effects of various adjunctive doses of sarizotan in the treatment of patients with neuroleptic‐induced tardive dyskinesia. www.ClinicalTrials.gov (accessed on 29 May 2016). ">NCT00310661 2006</a>; <a href="./references#CD000458-bbs2-0049" title="NCT00845000 . Acute effects of SCH 420814 on dyskinesia and Parkinsonism in levodopa treated patients. www.ClinicalTrials.gov (accessed on 29 May 2016). ">NCT00845000 2009</a>; <a href="./references#CD000458-bbs2-0050" title="O'SuilleabhainP , DeweyRB . A randomized trial of amantadine in Huntington disease. Archives of Neurology2003;60(7):996‐8. ">O'Suilleabhain 2003</a>). Participants in two RCTs were not on stable antipsychotic medication before and during the study and were consequently not eligible for inclusion (<a href="./references#CD000458-bbs2-0038" title="JankovicJ . Treatment of hyperkinetic movement disorders with tetrabenazine: a double‐blind crossover study. Annals of Neurology1982;11(1):41‐7. ">Jankovic 1982</a>; <a href="./references#CD000458-bbs2-0045" title="LiebermanJA , AlvirJ , MukherjeeS , KaneJM . Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Archives of General Psychiatry1989;46(10):908‐13. PerovichRM , LiebermanJA , FleischhackerWW , AlvirJ . The behavioral toxicity of bromocriptine in patients with psychiatric illness. Journal of Clinical Psychopharmacology1989;9(6):417‐22. ">Lieberman 1989</a>). Two RCTs evaluated selegiline, an intervention that is not relevant for this review: <a href="./references#CD000458-bbs2-0034" title="GoffDC , RenshawPF , Sarid‐SegalO , DreyfussDA , AmicoET , CirauloDA . A placebo‐controlled trial of selegiline (L‐deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry1993;33(10):700‐6. ">Goff 1993</a> is included in the update of the 'Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia' Cochrane Review (<a href="./references#CD000458-bbs2-0121" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a>); and <a href="./references#CD000458-bbs2-0056" title="StearnsAI , SambunarisA , ElkashefAM , IssaF , EganMF , WyattRJ . Selegiline for negative symptoms and tardive dyskinesia. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9; New York, USA. American Psychiatric Association, 1996. ">Stearns 1996</a> also reported no usable data so was excluded from the <a href="./references#CD000458-bbs2-0121" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a> review as well as from this review. </p> <p>Twenty‐four studies had to be excluded because data were all unusable, in 18 of these as a result of failure to report outcomes from the first phase before cross‐over. We contacted authors of six of these 18 studies but received no reply (<a href="./references#CD000458-bbs2-0025" title="DoongajiDR , JesteDV , JapeNM . Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia. Journal of Clinical Psychopharmacology1982;2(6):376‐9. ">Doongaji 1982</a>; <a href="./references#CD000458-bbs2-0037" title="HemnaniTJ , DashputraPG , SardaRN . Metoclopramide in tardive dyskinesia. Indian Journal of Pharmacology1982;14(4):309‐12. HemnaniTJ , DashputraPG , SardaRN . Metoclopramide in tardive dyskinesia. Indian Journal of Psychiatry1983;25(2):134‐7. ">Hemnani 1982</a>; <a href="./references#CD000458-bbs2-0039" title="JesteDV , CutlerNR , KaufmanCA , KaroumF . Low‐dose apomorphine and bromocriptine in neuroleptic‐induced movement disorders. Biological Psychiatry1983;18(9):1085‐91. ">Jeste 1983</a>; <a href="./references#CD000458-bbs2-0044" title="LiebermanJ , PollackS , LesserM , KaneJ . Pharmacologic characterization of tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(4):254‐60. ">Lieberman 1988</a>; <a href="./references#CD000458-bbs2-0047" title="NasrallahHA , DunnerFJ , McCalley‐WhittersM , SmithRE . Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management. Journal of Clinical Psychiatry1986;47(2):56‐9. ">Nasrallah 1986</a>; <a href="./references#CD000458-bbs2-0057" title="TammingaCA , ChaseTN . Bromocriptine and CF 25‐397 in the treatment of tardive dyskinesia. Archives of Neurology1980;37(4):204‐5. ">Tamminga 1980</a>); and since they were all published over 25 years ago and we assumed we would be very unlikely to receive a reply with data so many years later, they were excluded. We did not identify up‐to‐date contact details of authors for 12 of 18 cross‐over studies and decided to also exclude them as they were published 20 to 45 years ago and again we assumed we would be very unlikely to receive a reply with data so many years later (<a href="./references#CD000458-bbs2-0013" title="AngusS , SugarsJ , BoltezarR , KoskewichS , SchneiderNM . A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology1997;17(2):88‐91. ">Angus 1997</a>; <a href="./references#CD000458-bbs2-0015" title="AubergerS , GreilW , RutherE . Tiapride in the treatment of tardive dyskinesia. A double‐blind study. Pharmacopsychiatry1985;18(1):61‐2. [MEDLINE: 82248457; PMID 6124989] GreilW , AubergerS , HaagH , RutherE . Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations. Neuropsychobiology1985;14(1):17‐22. ">Auberger 1985</a>; <a href="./references#CD000458-bbs2-0016" title="BatemanDN , DuttaDK , McClellandHA , RawlinsMD . Metoclopramide and haloperidol in tardive dyskinesia. British Journal of Psychiatry1979;135:505‐8. BatemanDN , DuttaDK , McClellandHA , RawlinsMD . The effect of metoclopramide and haloperidol on tardive dyskinesia. British Journal of Pharmacology1979;66(3):475‐6. ">Bateman 1979</a>; <a href="./references#CD000458-bbs2-0017" title="BraunA , MouradianMM , MohrE , FabbriniG , ChaseTN . Selective D‐1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. Journal of Neurology, Neurosurgery, and Psychiatry1989;52(5):631‐5. ">Braun 1989</a>; <a href="./references#CD000458-bbs2-0018" title="BrowneJ , SilverH , MartinR , HartR , MergenerM , WilliamsP . The use of clonidine in the treatment of neuroleptic induced tardive dyskinesia. Journal of Clinical Psychopharmacology1986;6(2):88‐92. ">Browne 1986a</a>; <a href="./references#CD000458-bbs2-0019" title="ChienCP , JungK , Ross‐TownsendA . Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1978;14(2):20‐2. [MEDLINE: 78179481] ">Chien 1978</a>; <a href="./references#CD000458-bbs2-0021" title="DelwaidePJ , DesseillesM . Controlled therapeutic study of spontaneous bucco‐linguo‐facial dyskinesias (author's translation) [Etude therapeutique controlee des dyskinesies bucco‐linguo‐faciales spontanees]. Semaine des Hopitaux1979;55(35‐6):1585‐9. [MEDLINE: 79178844] ">Delwaide 1979</a>; <a href="./references#CD000458-bbs2-0029" title="FreemanHL , SoniSD , CarpenterL . A controlled trial of oxypertine in tardive dyskinesia. International Pharmacopsychiatry1980;15(5):281‐91. [MEDLINE: 81263210] ">Freeman 1980</a>; <a href="./references#CD000458-bbs2-0030" title="GardosG , GranacherRP , ColeJO , SniffinC . The effects of papaverine in tardive dyskinesia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry1979;3(5‐6):543‐50. ">Gardos 1979</a>; <a href="./references#CD000458-bbs2-0032" title="GloverO . Alternative treatment modalities for drug induced psychomotor dysfunctions. PhD dissertation submitted to the Wright Institute1980:150. ">Glover 1980</a>; <a href="./references#CD000458-bbs2-0033" title="Godwin AustenRB , ClarkeT . Persistant phenothiazine dyskinesia treated with tetrabenazine. British Medical Journal1971;4:25‐6. ">Godwin Austen 1971</a>; <a href="./references#CD000458-bbs2-0058" title="ViukariM , LinnoilaM . Effect of methyldopa on tardive dyskinesia in psychogeriatric patients. Current Therapeutic Research, Clinical and Experimental1975;18(3):417‐24. ">Viukari 1975</a>). No usable outcome data were reported in the six remaining studies. We contacted authors of <a href="./references#CD000458-bbs2-0012" title="AlpertM , FriedhoffAJ , DiamondF . Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia. Advances in Neurology1983;37:253‐8. ">Alpert 1983</a> and <a href="./references#CD000458-bbs2-0023" title="DiehlA , BrausDF , BuchelC , KrummB , Medori , R , GattazWF . Tardive dyskinesia: pergolid, a possible therapeutic option [Tardive Dyskinesien: Pergolid als mögliche therapeutische Option]. Psychiatrische Praxis2003;30:333‐7. DiehlA , DittmannRW , GattazW , RubinM , HundemerHP . Low dose pergolide in the treatment of tardive dyskinesia (td): a double blind, placebo controlled randomised cross over trial. 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999:243. DiehlA , HundemerHP , RubinM , DittmannRW , GattazW . Low‐dose pergolide in the treatment of tardive dyskinesia (TD): a double‐blind, placebo‐controlled randomized cross‐over trial. Journal of the European College of Neuropsychopharmacology. 1999:S359. [MEDLINE: 21040493] ">Diehl 1999</a> but received no reply. We could not identify up‐to‐date contact details for authors of <a href="./references#CD000458-bbs2-0035" title="GreendykeRM , WebsterJC , KimJ , KimH . Lack of efficacy of pindolol in tardive dyskinesia. American Journal of Psychiatry1988;145(10):1318‐9. ">Greendyke 1988</a>, <a href="./references#CD000458-bbs2-0046" title="LudatscherJI . Stable remission of tardive dyskinesia by L‐dopa. Journal of Clinical Psychopharmacology1989;9(1):39‐41. ">Ludatscher 1989</a>, <a href="./references#CD000458-bbs2-0051" title="RekerD , AndersonB , YackulicC . Naloxone, tardive dyskinesia, and endogenous beta‐endorphin. Psychiatry Research1982;7(3):321‐4. ">Reker 1982</a> and <a href="./references#CD000458-bbs2-0054" title="SilverH , GeraisyN , SchwartzM . No difference in the effect of biperiden and amantadine on Parkisonian‐ and tardive dyskinesia‐type involuntary movements: a double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. Journal of Clinical Psychiatry1995;56(4):167‐70. SilverH , GeraisyN , SchwartzM . No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: A double‐ blind crossover, PLACEBO‐controlled study in medicated chronic schizophrenic patients. Journal of Clinical Psychiatry1995;56(9):435. ">Silver 1995</a>. These six studies were also excluded as they were published 15 to 30 years ago and again we assumed we would be very unlikely to receive a reply with data so many years later. </p> <p>See <a href="./references#CD000458-sec-0251" title="">Characteristics of excluded studies</a> for more details on each excluded study. </p> <section id="CD000458-sec-0134"> <h5 class="title">Studies awaiting classification</h5> <p>There are currently no studies awaiting classification.</p> </section> <section id="CD000458-sec-0135"> <h5 class="title">Ongoing studies</h5> <p>As far as we are aware, there are currently no ongoing studies.</p> </section> </section> </section> <section id="CD000458-sec-0136"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD000458-fig-0002">Figure 2</a> and <a href="#CD000458-fig-0003">Figure 3</a> for graphical overviews of the risk of bias in the included studies, and <a href="./references#CD000458-sec-0250" title="">Characteristics of included studies</a> for details. </p> <section id="CD000458-sec-0137"> <h4 class="title">Allocation</h4> <p>Reporting of randomisation and allocation concealment was poor overall. No study explicitly reported the method for sequence generation other than using the word "randomized" and consequently all studies were rated at unclear risk of bias for sequence generation. Only two studies were rated at low risk of bias for allocation concealment. <a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a> reported the allocation of participants by an external site while <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a> used sealed opaque envelopes. The remaining studies were rated at unclear risk of bias for allocation concealment. </p> </section> <section id="CD000458-sec-0138"> <h4 class="title">Blinding</h4> <p>Although all studies were stated to be conducted on a double‐blind basis, not all explicitly described how this was undertaken and none tested the blindness of raters, clinicians and trial participants. <a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>, <a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>, <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>, <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a> and <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a> described how the participants and personnel were blinded and were rated at low risk of performance bias. <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>, <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>, and <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a> described how the raters were blinded and were rated at low risk of detection bias. The remaining studies were rated at unclear risk of performance or detection bias, or both. </p> </section> <section id="CD000458-sec-0139"> <h4 class="title">Incomplete outcome data</h4> <p>In four studies all randomised participants completed the study and were included in analyses; these were rated at low risk of attrition bias (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>; <a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>). Three studies did not report fully on attrition and were at unclear risk of bias (<a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>; <a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>). Three studies had 30% or greater loss to follow‐up (<a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>), or unbalanced loss to follow‐up between groups (<a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>), and did not report outcomes for participants lost to follow‐up. These studies were rated at high risk of attrition bias. In all cases, however, we tried to ensure that every person randomised was analysed. </p> </section> <section id="CD000458-sec-0140"> <h4 class="title">Selective reporting</h4> <p>Data in this review originates from published reports. Expected outcomes (impact on tardive dyskinesia symptoms, adverse events) were not reported sufficiently for most of the trials. In addition, we have had no opportunity to see protocols of these trials to compare the outcomes reported in the full publications with what was planned and measured during the conduct of the trial. Three studies were rated at unclear risk of reporting bias as it was unclear whether all outcomes were fully reported (<a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>). The remaining seven studies were at high risk of reporting bias as they failed to fully report all measured outcomes. </p> </section> <section id="CD000458-sec-0141"> <h4 class="title">Other potential sources of bias</h4> <p>All studies had small or very small sample sizes. Three of the studies used a cross‐over design (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>; <a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>); four of the studies had the drugs used in the trials provided by pharmaceutical companies (<a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>; <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>); and in six studies no details of funding were given (<a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>; <a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>). </p> <p>Nevertheless, we rated four studies at low risk bias as they seemed to be free from other sources of bias and baseline characteristics were balanced between groups (<a href="./references#CD000458-bbs2-0002" title="ChenJ , ZhongX , CaoZ . A double‐blind auto‐control study on the effect of bromocriptine on tardive dyskinesia. Chinese Journal of Pharmaco Epiolemiology1995;4(4):203‐5. [MEDI95S5] ">Chen 1995</a>; <a href="./references#CD000458-bbs2-0003" title="HebenstreitGF , HoffmannH , HoffmannW , PittnerH . Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics [Betablockade mit Celiprolol bei Neuroleptikabehandelten Patienten mit Tardiver Dyskinesie]. Wiener Klinische Wochenschrift1986;98(12):388‐92. [MEDLINE: 86291396] ">Hebenstreit 1986</a>; <a href="./references#CD000458-bbs2-0005" title="KarniolG , GiampietroAC , MouraDSP , VilelaWA , OliveiraMA , ZuardiAW . A double‐blind study of the effect of L‐dopa in psychotic patients with tardive dyskinesia [Estudo duplo‐cego sobre a ação de L‐dopa em pacientes psicóticos com discinesia tardia]. Acta Psiquiatrica y Psicologica de America Latina1983;29:261‐6. ">Karniol 1983</a>; <a href="./references#CD000458-bbs2-0010" title="SoniSD , FreemanHL , BamrahJS , SampathG . Oxypertine in tardive dyskinesia: a long‐term controlled study. Acta Psychiatrica Scandinavica1986;74(5):446‐50. ">Soni 1986</a>). Five studies were at unclear risk of other bias as insufficient information was available to make a judgement otherwise (<a href="./references#CD000458-bbs2-0004" title="HuangCC , WangRIH , HasegawaA , AlvernoL . Evaluation of reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology Bulletin1980;16:41‐3. HuangCC , WangRIH , HasegawaA , AlvernoL . Reserpine and alpha‐methyldopa in the treatment of tardive dyskinesia. Psychopharmacology1981;73:359‐62. ">Huang 1981</a>; <a href="./references#CD000458-bbs2-0006" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000458-bbs2-0007" title="PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Effects of amantadine on tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. Clinical Neuropharmacology2010;33(6):271‐5. PappaS , TsouliS , ApostolouG , MavreasV , KonitsiotisS . Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double‐blind, placebo‐controlled study. 9th World Congress of Biological Psychiatry; 28 June‐2 July 2009; Paris, France. 2009:171. PappaS , TzouliS , MavreasV , KonitsiotisS . Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Schizophrenia Research2012;136:S358. ">Pappa 2010</a>; <a href="./references#CD000458-bbs2-0008" title="RustM . Tiapride treatment of tardive dyskinesia due to long‐term neuroleptic treatment. Semaine des Hopitaux1984;60(30):2195‐6. ">Rust 1984</a>; <a href="./references#CD000458-bbs2-0009" title="SimpsonGM , YadalamKG , StephanosMJ . Double‐blind carbidopa‐levodopa and placebo study in tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(Suppl 4):S49‐51. ">Simpson 1988</a>). Finally, <a href="./references#CD000458-bbs2-0001" title="BurumaOJS , RoosRAC , BruynGW . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989] RoosRAC , BurumaOJS , BruynGW , KempB , vd VeldeEA , ZelvelderWG . Tiapride in Huntington's chorea and tardive dyskinesia. A double‐blind, placebo controlled crossover clinical trial [Tiaprid bij chorea van Huntington en tardieve dyskinesie. Een dubbelblind, placebo‐gecontroleerd cross‐overonderzoek]. Tijdschrift voor Geneesmiddelenonderzoek1982;7(2):1234‐9. ">Buruma 1982</a> was at high risk of other bias as the placebo group contained participants more severely affected by TD at baseline. </p> </section> </section> <section id="CD000458-sec-0142"> <h3 class="title" id="CD000458-sec-0142">Effects of interventions</h3> <p>See: <a href="./full#CD000458-tbl-0001"><b>Summary of findings for the main comparison</b> NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000458-tbl-0002"><b>Summary of findings 2</b> NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000458-tbl-0003"><b>Summary of findings 3</b> DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000458-tbl-0004"><b>Summary of findings 4</b> DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia</a> </p> <section id="CD000458-sec-0143"> <h4 class="title">1. Comparison 1: noradrenergic drugs versus placebo</h4> <section id="CD000458-sec-0144"> <h5 class="title">1.1 TD symptoms</h5> <p>We had chosen 'any improvement in TD symptoms of more than 50% on any TD scale – any time period' as a primary outcome. Although the data we found in trials did not fit this exactly we feel that the outcome 'not improved to a clinically important extent' fits best with what we had hoped to find. </p> <section id="CD000458-sec-0145"> <h6 class="title">1.1.1 Not improved to a clinically important extent</h6> <p>The overall results for 'clinically relevant improvement' found a significant benefit of alpha‐methyldopa over placebo after 2 weeks' treatment (low‐quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.14 to 0.80; <a href="./references#CD000458-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD000458-sec-0146"> <h6 class="title">1.1.2 Not any improvement</h6> <p>For the outcome of 'any improvement in TD symptoms' we found no significant difference between noradrenergic drugs (alpha‐methyldopa, celiprolol) and placebo after 2 to 13 weeks' treatment (2 trials, 55 people; RR 0.91, 95% CI 0.65 to 1.27; I² = 0%, <a href="./references#CD000458-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD000458-sec-0147"> <h6 class="title">1.1.3 Deterioration of symptoms</h6> <p>There was no significant difference in deterioration of symptoms between people allocated to alpha‐methyldopa or placebo after 2 weeks' treatment (very low quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.02 to 7.32; <a href="./references#CD000458-fig-0007" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD000458-sec-0148"> <h5 class="title">1.2 Leaving the study early</h5> <p>Using celiprolol did not significantly increase the chances of a person leaving the study early compared with placebo after 13 weeks' treatment (very low quality evidence, 1 trial, 35 people; RR 5.28, 95% CI 0.27 to 102.58; <a href="./references#CD000458-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD000458-sec-0149"> <h5 class="title">1.3 Quality of life</h5> <p>There was no significant difference in quality of life between people allocated to celiprolol or placebo after 13 weeks' treatment (very low quality evidence, 1 trial, 35 people; RR 0.87, 95% CI 0.68 to 1.12; <a href="./references#CD000458-fig-0009" title="">Analysis 1.5</a>). </p> <p>We did not identify any studies that reported on hospital and service utilisation outcomes, economic outcomes, behaviour, or cognitive state. </p> </section> <section id="CD000458-sec-0150"> <h5 class="title">1.4 Subgroup analysis</h5> <section id="CD000458-sec-0151"> <h6 class="title">1.4.1 Type of compound</h6> <p>There were no significant subgroup differences (I² = 0%, P = 0.52, <a href="./references#CD000458-fig-0006" title="">Analysis 1.2</a>) for alpha‐methyldopa versus placebo (RR 0.33, 95% CI 0.02 to 7.32; 20 participants, 1 study) and celiprolol versus placebo (RR 0.92, 95% CI 0.66 to 1.28; 35 participants, 1 study) on 'not any improvement in TD symptoms', the only outcome for this comparison that evaluated more than one non‐antipsychotic catecholaminergic compound. </p> </section> <section id="CD000458-sec-0152"> <h6 class="title">1.4.2 Duration of follow‐up</h6> <p>Any effects that noradrenergic drugs may have did not clearly change in relation to duration of follow‐up compared with placebo. </p> </section> <section id="CD000458-sec-0153"> <h6 class="title">1.4.3 Clinical stage: recent onset TD</h6> <p>It was not possible to evaluate whether those with recent onset TD responded differently to those with more established problems, since no trial reported data for groups with different durations of TD that could be extracted for separate analyses. </p> </section> </section> <section id="CD000458-sec-0154"> <h5 class="title">1.5 Heterogeneity</h5> <p>Data were homogeneous. We did not detect clinical, methodological or statistical heterogeneity as described in <a href="#CD000458-sec-0085">Assessment of heterogeneity</a>. </p> </section> <section id="CD000458-sec-0155"> <h5 class="title">1.6 Sensitivity analyses</h5> <section id="CD000458-sec-0156"> <h6 class="title">1.6.1 Implication of randomisation</h6> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. Only one study was included for the primary outcome: consequently this sensitivity analysis could not be performed. </p> </section> <section id="CD000458-sec-0157"> <h6 class="title">1.6.2 Assumptions for lost binary data</h6> <p>The above results are based on data as presented in the original study reports, with the assumption that those who left early before the end of the trial had not improved (see <a href="#CD000458-sec-0078">Dealing with missing data</a>). We planned to test the sensitivity of the results to this assumption, but all randomised participants were reported for the primary outcome 'no clinically important improvement in TD symptoms'. Therefore, we could not undertake this sensitivity analysis. If there had been a substantial difference, we would have reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD000458-sec-0158"> <h6 class="title">1.6.3 Risk of bias</h6> <p>We planned to exclude trials that we judged to be at high risk of bias across one or more of the domains, but only one study was included for the primary outcome. Consequently this sensitivity analysis could not be performed. </p> </section> <section id="CD000458-sec-0159"> <h6 class="title">1.6.4 Imputed values</h6> <p>We would have undertaken a sensitivity analysis to assess the effects of including data from cluster randomised trials where we used imputed values for ICC in calculating the design effect. No cluster randomised trials were included. </p> </section> <section id="CD000458-sec-0160"> <h6 class="title">1.6.5 Fixed and random effects</h6> <p>We also synthesised data using a random effects model. This did not alter the effect estimates or CIs (analysis not shown). </p> </section> </section> </section> <section id="CD000458-sec-0161"> <h4 class="title">2. Comparison 2: noradrenergic drugs versus dopaminergic drugs</h4> <section id="CD000458-sec-0162"> <h5 class="title">2.1 TD symptoms</h5> <section id="CD000458-sec-0163"> <h6 class="title">2.1.1 Not improved to a clinically important extent</h6> <p>The overall results for 'clinically relevant improvement' found no significant benefit of alpha‐methyldopa over reserpine after 2 weeks' treatment (1 trial, 20 people; RR 0.60, 95% CI 0.19 to 1.86; <a href="./references#CD000458-fig-0010" title="">Analysis 2.1</a>). </p> </section> <section id="CD000458-sec-0164"> <h6 class="title">2.1.2 Not any improvement</h6> <p>We could not estimate the effect of alpha‐methyldopa compared with reserpine on any improvement in TD symptoms as no events were reported (1 trial, 20 participants, <a href="./references#CD000458-fig-0011" title="">Analysis 2.2</a>). </p> </section> <section id="CD000458-sec-0165"> <h6 class="title">2.1.3 Deterioration of symptoms</h6> <p>We could not estimate the effect of alpha‐methyldopa compared with reserpine on deterioration of TD symptoms as no events were reported (1 trial, 20 participants, <a href="./references#CD000458-fig-0012" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD000458-sec-0166"> <h5 class="title">2.2 Heterogeneity, subgroup‐ and sensitivity analyses</h5> <p>Only one study was included in this comparison: consequently subgroup and sensitivity analyses could not be undertaken and there was no heterogeneity. </p> </section> </section> <section id="CD000458-sec-0167"> <h4 class="title">3. Comparison 3: dopaminergic drugs versus placebo</h4> <section id="CD000458-sec-0168"> <h5 class="title">3.1 TD symptoms</h5> <section id="CD000458-sec-0169"> <h6 class="title">3.1.1 Not improved to a clinically important extent</h6> <p>The overall results for 'clinically relevant improvement' found a significant benefit of reserpine over placebo after 2 weeks' treatment (low‐quality evidence, 1 trial, 20 people; RR 0.52, 95% CI 0.29 to 0.96; <a href="./references#CD000458-fig-0013" title="">Analysis 3.1</a>). </p> </section> <section id="CD000458-sec-0170"> <h6 class="title">3.1.2 Not any improvement</h6> <p>For the outcome of 'any improvement in TD symptoms' we found no significant difference between dopaminergic drugs (Carbidopa/levodopa, L‐dopa, reserpine) and placebo after 2 to 6 weeks' treatment (3 trials, 57 people;RR 0.60, 95% CI 0.35 to 1.03; I² = 0%, <a href="./references#CD000458-fig-0014" title="">Analysis 3.2</a>). </p> </section> <section id="CD000458-sec-0171"> <h6 class="title">3.1.3 Deterioration of symptoms</h6> <p>There was no significant difference in deterioration of symptoms between people allocated to dopaminergic drugs (carbidopa/levodopa, reserpine) or placebo after 2 to 6 weeks' treatment (very low quality evidence, 2 trials, 37 people; RR 1.18, 95% CI 0.35 to 3.99; I² = 0%, <a href="./references#CD000458-fig-0015" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD000458-sec-0172"> <h5 class="title">3.2 Mental state</h5> <p>There was no significant difference between oxypertine and placebo on deterioration of mental state after 24 weeks' treatment (very low quality evidence, 1 trial, 42 people; RR 2.20, 95% CI 0.22 to 22.45; <a href="./references#CD000458-fig-0016" title="">Analysis 3.4</a>). </p> </section> <section id="CD000458-sec-0173"> <h5 class="title">3.3 Leaving the study early</h5> <p>Using dopaminergic drugs (amantadine, bromocriptine, carbidopa/levodopa, oxypertine, tiapride) did not significantly affect the chances of a person leaving the study early compared with placebo after 2 to 24 weeks' treatment (very low quality evidence, 6 trials, 163 people; RR 1.29, 95% CI 0.65 to 2.54; I² = 58%, <a href="./references#CD000458-fig-0017" title="">Analysis 3.5</a>). </p> </section> <section id="CD000458-sec-0174"> <h5 class="title">3.4 Subgroup analysis</h5> <section id="CD000458-sec-0175"> <h6 class="title">3.4.1 Type of compound</h6> <p>There were no significant subgroup differences (I² = 0%, P = 0.90, <a href="./references#CD000458-fig-0014" title="">Analysis 3.2</a>) for reserpine versus placebo (RR 0.33, 95% CI 0.02 to 7.32; 20 participants, 1 study), L‐dopa versus placebo (RR 0.67, 95% CI 0.35 to 1.27; 20 participants, 1 study), and carbidopa/levodopa versus placebo (RR 0.59, 95% CI 0.26 to 1.36; 17 participants, 1 study) on 'not any improvement in TD symptoms'. For 'deterioration of TD symptoms' there were no significant subgroup differences (I² = 0%, P = 0.32, <a href="./references#CD000458-fig-0015" title="">Analysis 3.3</a>) for reserpine versus placebo (RR 0.33, 95% CI 0.02 to 7.32; 20 participants, 1 study) and carbidopa/levodopa versus placebo (RR 1.78, 95% CI 0.44 to 7.25; 17 participants, 1 study). Finally, for 'acceptability of treatment: leaving the study early', there were subgroup differences (I² = 54.5%, P = 0.14, <a href="./references#CD000458-fig-0017" title="">Analysis 3.5</a>) for the subgroups that reported events, oxypertine versus placebo (RR 1.73, 95% CI 0.83 to 3.58; 42 participants, 1 study) and carbidopa/levodopa versus placebo (RR 0.18, 95% CI 0.01 to 3.27; 17 participants, 1 study; see '3.5 Heterogeneity' below). </p> </section> <section id="CD000458-sec-0176"> <h6 class="title">3.4.2 Duration of follow‐up</h6> <p>Any effects that dopaminergic drugs may have did not clearly change in relation to duration of follow‐up compared with placebo. </p> </section> <section id="CD000458-sec-0177"> <h6 class="title">3.4.3 Clinical stage: recent onset TD</h6> <p>It was not possible to evaluate whether those with recent onset TD responded differently to those with more established problems, since no trial reported data for groups with different durations of TD that could be extracted for separate analyses. </p> </section> </section> <section id="CD000458-sec-0178"> <h5 class="title">3.5 Heterogeneity</h5> <p>Data were mostly homogeneous. We detected statistical heterogeneity (I² = 58%, P = 0.12) as described in <a href="#CD000458-sec-0085">Assessment of heterogeneity</a> for the outcome 'acceptability of treatment: leaving the study early'. Six studies reported on this outcome, but only two reported any events. One of these two studies reported an effect estimate favouring placebo over oxypertine after 24 weeks' treatment and the other study reported an effect estimate favouring carbidopa/levodopa over placebo after 6 weeks' treatment, but none of the studies reported statistically significant differences between groups (see <a href="./references#CD000458-fig-0017" title="">Analysis 3.5</a> and '3.4.1 Type of compound' above). </p> </section> <section id="CD000458-sec-0179"> <h5 class="title">3.6 Sensitivity analysis</h5> <section id="CD000458-sec-0180"> <h6 class="title">3.6.1 Implication of randomisation</h6> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. Only one study was included for the primary outcome: consequently this sensitivity analysis could not be performed. </p> </section> <section id="CD000458-sec-0181"> <h6 class="title">3.6.2 Assumptions for lost binary data</h6> <p>The above results are based on data as presented in the original study reports, with the assumption that those who left early before the end of the trial had not improved (see <a href="#CD000458-sec-0078">Dealing with missing data</a>). We planned to test the sensitivity of the results to this assumption, but all randomised participants were reported for the primary outcome 'no clinically important improvement in TD symptoms'. Therefore we could not undertake this sensitivity analysis. If there had been a substantial difference, we would have reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD000458-sec-0182"> <h6 class="title">3.6.3 Risk of bias</h6> <p>We planned to exclude trials that we judged to be at high risk of bias across one or more of the domains, but only one study was included for the primary outcome. Consequently this sensitivity analysis could not be performed. </p> </section> <section id="CD000458-sec-0183"> <h6 class="title">3.6.4 Imputed values</h6> <p>We would have undertaken a sensitivity analysis to assess the effects of including data from cluster randomised trials where we used imputed values for ICC in calculating the design effect. No cluster randomised trials were included. </p> </section> <section id="CD000458-sec-0184"> <h6 class="title">3.6.5 Fixed and random effects</h6> <p>We also synthesised data using a random‐effects model. This did not alter the effect estimate or CIs for the primary outcome (analyses not shown). </p> </section> </section> </section> <section id="CD000458-sec-0185"> <h4 class="title">4. Comparison 4: dopaminergic drugs versus other drugs</h4> <section id="CD000458-sec-0186"> <h5 class="title">4.1 TD symptoms</h5> <section id="CD000458-sec-0187"> <h6 class="title">4.1.1 Not improved to a clinically important extent</h6> <p>We found no significant benefit of tetrabenazine over haloperidol for 'no clinically relevant improvement after 18 weeks' treatment' (1 trial, 13 people; RR 0.93, 95% CI 0.45 to 1.95; <a href="./references#CD000458-fig-0018" title="">Analysis 4.1</a>). </p> </section> <section id="CD000458-sec-0188"> <h6 class="title">4.1.2 Not any improvement</h6> <p>For the outcome of 'any improvement in TD symptoms', we found no significant difference between tetrabenazine and haloperidol after 18 weeks' treatment (1 trial, 13 people; RR 0.39, 95% CI 0.05 to 2.83; <a href="./references#CD000458-fig-0019" title="">Analysis 4.2</a>). </p> </section> <section id="CD000458-sec-0189"> <h6 class="title">4.1.3 Deterioration of symptoms</h6> <p>There was no significant difference in deterioration of TD symptoms between people allocated to tetrabenazine or haloperidol after 18 weeks' treatment (1 trial, 13 people; RR 1.17, 95% CI 0.09 to 14.92; <a href="./references#CD000458-fig-0020" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD000458-sec-0190"> <h5 class="title">4.2 Leaving the study early</h5> <p>There was no significant difference between tetrabenazine and haloperidol in the chances of a person leaving the study early after 18 weeks' treatment (1 trial, 13 people; RR 0.23, 95% CI 0.01 to 4.00; <a href="./references#CD000458-fig-0021" title="">Analysis 4.4</a>). </p> </section> <section id="CD000458-sec-0191"> <h5 class="title">4.3 Heterogeneity, and subgroup and sensitivity analyses</h5> <p>Only one study was included in this comparison. Consequently, subgroup and sensitivity analyses could not be undertaken; and there was no heterogeneity. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000458-sec-0192" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000458-sec-0192"></div> <section id="CD000458-sec-0193"> <h3 class="title" id="CD000458-sec-0193">Summary of main results</h3> <section id="CD000458-sec-0194"> <h4 class="title">1. The search</h4> <p>This area of research does not seem to be active. The 2017 update has identified additional data, but most trials predate the year 2000: only one was carried out after, published in 2010. This could be because of reasons such as less concern with TD, or less emergence of the problem in research‐active communities because of more thoughtful use of antipsychotic drugs or loss of faith in non‐antipsychotic catecholaminergic drugs as a potential treatment. </p> </section> <section id="CD000458-sec-0195"> <h4 class="title">2. Few data</h4> <p>Only a little over 250 people have been included in this review. It is possible that real, and important, effects have not been highlighted because of the necessarily wide CIs of the findings. Many outcomes were not measured at all (see <a href="#CD000458-sec-0209">Overall completeness and applicability of evidence</a>), including one of our pre‐stated outcome measures. We may have been overambitious in hoping for some of these outcomes in TD trials but simple reporting of satisfaction with care or quality of life still does not seem too demanding and does remain of interest. </p> </section> <section id="CD000458-sec-0196"> <h4 class="title">3. Comparison 1: noradrenergic drugs versus placebo</h4> <section id="CD000458-sec-0197"> <h5 class="title">3.1 TD symptoms</h5> <p>Results from one study show that significantly more participants on alpha‐methyldopa than on placebo improved to a clinically important level at short term; however, our confidence in the evidence is low so further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </section> <section id="CD000458-sec-0198"> <h5 class="title">3.2 Acceptability of treatment</h5> <p>It is always unclear what leaving the study early means. It could be to do with the participant not accepting treatment for a series of reasons, or of participants finding the trial intolerable. It also could be a function of a trial design in which willing participants are still asked to leave because of some degree of protocol violation. In any event, one study reported that 2/17 participants left the celiprolol group compared with a 'not significantly different' 0/18 in the placebo group. </p> </section> <section id="CD000458-sec-0199"> <h5 class="title">3.3 Social confidence, social inclusion, social networks, or personalised quality of life </h5> <p>This group of outcomes was selected as being of importance to patients for the 2017 review update following a service user consultation. One study reported on 'no improvement in quality of life' and found no difference between celiprolol and placebo; however, we are uncertain about the results as the evidence is of very low quality. </p> <p>No studies comparing noradrenergic drugs versus placebo were identified that reported on adverse events or mental state. See <a href="./full#CD000458-tbl-0001">summary of findings Table for the main comparison</a> for a summary of the evidence. </p> </section> </section> <section id="CD000458-sec-0200"> <h4 class="title">4. Comparison 2: noradrenergic drugs versus dopaminergic drugs</h4> <section id="CD000458-sec-0201"> <h5 class="title">4.1 TD symptoms</h5> <p>Only one small, short duration trial reported on this comparison and found no difference between alpha‐methyldopa and reserpine on 'no clinically important improvement in TD'. The size and duration of the trial were so limited that only a treatment of very great potency could have really shown up as effective. </p> <p>No studies were identified that reported on adverse events, mental state, acceptability of treatment or social confidence, social inclusion, social networks, or personalised quality of life. </p> </section> </section> <section id="CD000458-sec-0202"> <h4 class="title">5. Comparison 3: dopaminergic drugs versus placebo</h4> <section id="CD000458-sec-0203"> <h5 class="title">3.1 TD symptoms</h5> <p>Results from one small study show that significantly more participants on reserpine than on placebo improved to a clinically important level at short term; however, our confidence in the evidence is low so further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. We are uncertain about the results on 'not any improvement in TD' and 'deterioration of TD'; evidence was of very low quality. </p> </section> <section id="CD000458-sec-0204"> <h5 class="title">3.2 Mental state</h5> <p>We are uncertain about the results on 'deterioration in mental state'; evidence was of very low quality. </p> </section> <section id="CD000458-sec-0205"> <h5 class="title">3.3 Acceptability of treatment</h5> <p>We are uncertain about the results on 'acceptability of treatment', measured by the number of participants leaving the study early; evidence was of very low quality. </p> <p>No studies were identified that reported on adverse events or social confidence, social inclusion, social networks, or personalised quality of life. See <a href="./full#CD000458-tbl-0003">summary of findings Table 3</a> for a summary of the evidence. </p> </section> </section> <section id="CD000458-sec-0206"> <h4 class="title">6. Comparison 4: dopaminergic drugs versus other drugs</h4> <section id="CD000458-sec-0207"> <h5 class="title">3.1 TD symptoms</h5> <p>Only one small, short‐duration trial reported on this comparison and found no difference between tetrabenazine and haloperidol on 'no clinically important improvement in TD', on 'not any improvement in TD', or on 'deterioration of TD'. The size and duration of the trial were so limited that only a treatment of very great potency could have really shown up as effective. </p> </section> <section id="CD000458-sec-0208"> <h5 class="title">3.2 Acceptability of treatment</h5> <p>None out of six participants left the tetrabenazine group compared with a 'not significantly different' two out of seven in the haloperidol group. </p> <p>No studies were identified that reported on adverse events, mental state, or social confidence, social inclusion, social networks, or personalised quality of life. </p> </section> </section> </section> <section id="CD000458-sec-0209"> <h3 class="title" id="CD000458-sec-0209">Overall completeness and applicability of evidence</h3> <section id="CD000458-sec-0210"> <h4 class="title">1. Completeness</h4> <p>Although we identified a large number of studies on the initial database search, the number of relevant studies was very small in comparison. The majority of studies selected were excluded because of inherent problems in the nature of their cross‐over design. That only eight studies were included in the final review does not give full justice to the fact that there has obviously been a reasonable amount of research in this area. This may have implications for future studies as discussed below. </p> <p>No outcomes in this review involve large numbers of people, and many outcomes reported no events. None of the studies reported on adverse events. Even if these small studies only set out to show efficacy, not reporting on adverse events is unexpected as non‐antipsychotic catecholaminergic compounds are associated with several side effects (<a href="./references#CD000458-bbs2-0128" title="TurjanskiN , LloydGG . Psychiatric side‐effects of medications: recent developments. Advances in Psychiatric Treatment2005;11(1):58‐70. ">Turjanski 2005</a>). In addition, there were very few data on the patient‐designated important outcomes of social confidence, social inclusion, social networks, or personalised quality of life; and there were no data on hospital and service utilisation outcomes, economic outcomes, behaviour or cognitive response. </p> </section> <section id="CD000458-sec-0211"> <h4 class="title">2. Applicability</h4> <p>All but one trial were hospital‐based but were nevertheless on people who would be recognisable in everyday care. Trials were set in North and South America, Asia, and Europe. Outcomes are understandable in terms of clinical practice. However, most of the interventions in question are experimental in the treatment of tardive dyskinesia. Therefore, should any of the non‐antipsychotic catecholaminergic compounds have had important effects, findings might only have been applicable for those compounds accepted as treatment of TD. </p> </section> </section> <section id="CD000458-sec-0212"> <h3 class="title" id="CD000458-sec-0212">Quality of the evidence</h3> <p>Overall, the quality of the evidence is low to very low. This means that we have limited to very little confidence in the effect estimates, and the true effect may be, or is likely to be, substantially different from the estimate of the effect. The main reasons for our low confidence in the evidence were as follows. </p> <p> <ol id="CD000458-list-0001"> <li> <p>Poor study methodology and reporting of methods resulting in downgrading evidence for risk of bias. Overall the quality of reporting of these trials was poor (see <a href="#CD000458-fig-0003">Figure 3</a>). Allocation concealment was not described; generation of the sequence was not explicit; studies were not clearly blinded and we are unsure if data are incomplete or selectively reported or if other biases were operating. </p> </li> <li> <p>Very small sample sizes resulting in downgrading evidence for imprecision. The largest trial in this review randomised only 50 people. A trial of this size is unable to detect subtle, yet important, differences due to an intervention with any confidence. In order to detect a 20% difference between groups, probably about 150 people are needed in each arm of the study (alpha 0.05, beta 0.8). </p> </li> <li> <p>Wide CIs (often due to low event rates) that included appreciable benefit or harm for the intervention as well as no effect, resulting in downgrading evidence for imprecision. </p> </li> </ol> </p> <p>The small trial sizes, along with the poor reporting of trials, is associated with an exaggeration of effect of the experimental treatment where an effect is detected (<a href="./references#CD000458-bbs2-0101" title="JűniP , AltmanDG , EggerM . Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ (Clinical research ed.)2001;323(7303):42‐6. [PUBMED: 11440947] ">Jűni 2001</a>). This is only evident for the outcome of ‘no clinically important improvement in TD' where there is indeed an effect favouring the noradrenergic and dopaminergic drugs compared with placebo (see <a href="./full#CD000458-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD000458-tbl-0003">summary of findings Table 3</a>). This finding may be real — but could equally be a function of biases or of chance. </p> </section> <section id="CD000458-sec-0213"> <h3 class="title" id="CD000458-sec-0213">Potential biases in the review process</h3> <section id="CD000458-sec-0214"> <h4 class="title">1. Missing studies</h4> <p>We made every effort to identify relevant trials. However, these studies are all small and it is likely that we have failed to identify other studies of limited power. It is likely that such studies would also not be in favour of the intervention group: if they had been so, it is more likely that they would have been published in accessible literature. We do not, however, think it likely that we have failed to identify large relevant studies. </p> </section> <section id="CD000458-sec-0215"> <h4 class="title">2. Introducing bias</h4> <p>We have tried to be balanced in our appraisal of the evidence but could have inadvertently introduced bias. We welcome comments or criticisms. New methods and innovations now make it possible to report data where, in the past, we could not report data at all or had to report data in a different way. We think the 'Summary of findings' tables to be a valuable innovation — but problematic to those not ‘blind’ to the outcome data. It is possible to ‘cherry pick’ significant findings for presentation in this table. We have tried to decrease the chance of doing this by asking a new reviewer (HB) to select outcomes relevant for this table before becoming familiar with the data. </p> </section> </section> <section id="CD000458-sec-0216"> <h3 class="title" id="CD000458-sec-0216">Agreements and disagreements with other studies or reviews</h3> <p>The only other relevant quantitative review we know of is the previous Cochrane Review (<a href="./references#CD000458-bbs2-0131" title="El‐SayehHG , Lyra da SilvaJP , RathboneJ , Soares‐WeiserK . Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2] ">El‐Sayeh 2006</a>). This update expands and improves this review but does not substantially change the conclusions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000458-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research." data-id="CD000458-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000458-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000458-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for 2015 and 2017 searching" data-id="CD000458-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Study flow diagram for 2015 and 2017 searching</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term." data-id="CD000458-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement." data-id="CD000458-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term." data-id="CD000458-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 4 Acceptability of treatment: Leaving the study early ‐ medium term." data-id="CD000458-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 4 Acceptability of treatment: Leaving the study early ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 5 Quality of life: No improvement ‐ medium term." data-id="CD000458-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 5 Quality of life: No improvement ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term." data-id="CD000458-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term." data-id="CD000458-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term." data-id="CD000458-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement." data-id="CD000458-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement." data-id="CD000458-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration." data-id="CD000458-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 4 Mental state: Deterioration ‐ medium term." data-id="CD000458-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 4 Mental state: Deterioration ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 5 Acceptability of treatment: Leaving the study early." data-id="CD000458-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 5 Acceptability of treatment: Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term." data-id="CD000458-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term." data-id="CD000458-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term." data-id="CD000458-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000458-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/urn:x-wiley:14651858:media:CD000458:CD000458-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_t/tCD000458-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 4 Acceptability of treatment: Leaving the study early ‐ medium term." data-id="CD000458-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 4 Acceptability of treatment: Leaving the study early ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/media/CDSR/CD000458/image_n/nCD000458-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000458-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggestions for design of future studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<br/> Blindness: double, tested.<br/> Duration: 12 months beyond end of intervention at least.<br/> Raters: independent. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with antipsychotic‐induced tardive dyskinesia.*<br/> Age: any.<br/> Sex: both.<br/> History: any.<br/> N = 300.** </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Non‐antipsychotic catecholaminergic compound. N = 150.<br/> 2. Placebo: N = 150. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***<br/> Adverse effects: no clinically significant extrapyramidal adverse effects ‐ any time period***, use of any antiparkinsonism drugs, other important adverse events.<br/> Leaving the study early.<br/> Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.<br/> Compliance with drugs.<br/> Economic evaluations: cost‐effectiveness, cost‐benefit.<br/> General state: relapse, frequency and intensity of minor and major exacerbations.<br/> Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<br/> Distress among relatives: binary measure.<br/> Burden on family: binary measure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. </p> <p>** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<br/> *** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggestions for design of future studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000458-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Settings:</b> inpatients in Austria and the USA<br/> <b>Intervention:</b> NORADRENERGIC DRUGS (alpha‐methyldopa, celiprolol)<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NORADRENERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b><br/> (140 to 800) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/> (0.14 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated alpha‐methyldopa.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: deterioration</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (2 to 732) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/> (0.02 to 7.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated alpha‐methyldopa.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies rating this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies rating this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment: Leaving the study early</b> </p> <p>follow‐up: 13 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.28</b> <br/> (0.27 to 102.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated celiprolol.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No improvement in quality of life</b> </p> <p>follow‐up: 13 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>944 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>822 per 1000</b><br/> (642 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/> (0.68 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated celiprolol.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, blinding of outcome assessors was not described.<br/> <sup>2</sup> Downgraded one step for imprecision: few events and small sample size.<br/> <sup>3</sup> Downgraded two steps for imprecision: few events, small sample size and wide CI that includes both no effect and appreciable benefit for intervention group.<br/> <sup>4</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000458-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in the USA<br/> <b>Intervention:</b> NORADRENERGIC DRUGS (alpha‐methyldopa)<br/> <b>Comparison:</b> DOPAMINERGIC DRUGS (reserpine) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOPAMINERGIC DRUGS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NORADRENERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.60</b><br/> (0.19 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1,000<br/> (95 to 930) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: Deterioration</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Among the 20 participants no events were reported.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability of treatment: Leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately.<br/> <sup>2</sup> Downgraded two steps for imprecision: few events, very small sample size, and wide CI that includes both appreciable benefit and appreciable harm for intervention group as well as no effect.<br/> <sup>3</sup> Downgraded two steps for imprecision: no events were reported, effect estimate cannot be calculated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000458-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Settings:</b> inpatients in the UK and the USA<br/> <b>Intervention:</b> DOPAMINERGIC DRUGS (carbidopa/levodopa, oxypertine, reserpine)<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DOPAMINERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b><br/> (290 to 960) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b> <br/> (0.29 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated reserpine.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: Deterioration</b> </p> <p>follow‐up: 2‐6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/> (58 to 665) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (0.35 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included studies evaluated reserpine and carbidopa/levodopa.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies rating this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General mental state: Deterioration</b> </p> <p>follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/> (10 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.2</b> <br/> (0.22 to 22.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study evaluated oxypertine.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment: Leaving the study early</b> </p> <p>follow‐up: 2‐24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/> (72 to 282) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> <br/> (0.65 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only two studies (59 participants) evaluating carbidopa/levodopa and oxypertine reported any events for this outcome. 4 studies evaluating amantadine, bromocriptine, and tiapride reported no events and consequently no estimates could be made for these 3 compounds. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was designated to be of importance, especially to patients. We found no studies rating this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, blinding of outcome assessors was not described.<br/> <sup>2</sup> Downgraded one step for imprecision: few events and small sample size.<br/> <sup>3</sup> Downgraded two steps for imprecision: few events, small sample size and wide CI that includes both no effect and appreciable benefit for intervention group.<br/> <sup>4</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, attrition was high (45%).<br/> <sup>5</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, attrition was high (45%) or unbalanced between groups (25% vs. 0%).<br/> <sup>6</sup> Downgraded one step for inconsistency: statistical heterogeneity was high (I² = 58%).<br/> <sup>7</sup> Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000458-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in the USA<br/> <b>Intervention:</b> DOPAMINERGIC DRUGS (tetrabenazine)<br/> <b>Comparison:</b> OTHER DRUGS (haloperidol) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OTHER DRUGS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOPAMINERGIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: No clinically important improvement</b> </p> <p>follow‐up: 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b><br/> (0.45 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>714 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1000<br/> (321 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tardive dyskinesia: Deterioration</b> </p> <p>follow‐up: 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.17</b><br/> (0.09 to 14.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/> (13 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> </p> <p>‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acceptability of treatment: Leaving the study early</b> </p> <p>follow‐up: 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.23</b><br/> (0.01 to 4.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (3 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies reporting on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately.<br/> <sup>2</sup> Downgraded two steps for imprecision: few events, very small sample size, and wide CI that includes both appreciable benefit and appreciable harm for intervention group as well as no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000458-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0120" title="Soares‐WeiserK , MobsyC , HollidayE . Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews1997, Issue 2. [DOI: 10.1002/14651858.CD000204] ">Soares‐Weiser 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0069" title="BhoopathiPS , Soares‐WeiserK . Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2] ">Bhoopathi 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0086" title="EssaliA , DeirawanH , Soares‐WeiserK , AdamsCE . Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3] ">Essali 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0124" title="TammenmaaI , McGrathJ , SailasE , Soares‐WeiserK . Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD000207] ">Tammenmaa 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐aminobutyric acid agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0059" title="AlabedS , LatifehY , MohammadHA , RifaiA . Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3] ">Alabed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0121" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroleptic reduction and/or cessation and neuroleptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0122" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐neuroleptic catecholaminergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000458-bbs2-0123" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the series</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/full#CD000458-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000458-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NORADRENERGIC DRUGS vs PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.14, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alpha‐methyldopa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.14, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: 2. Not any improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Alpha‐methyldopa ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Celiprolol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: 3. Deterioration ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alpha‐methyldopa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acceptability of treatment: Leaving the study early ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.28 [0.27, 102.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Celiprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.28 [0.27, 102.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: No improvement ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Celiprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NORADRENERGIC DRUGS vs PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000458-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.19, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alpha‐methyldopa versus Reserpine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.19, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: 2. Not any improvement ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Alpha‐methyldopa versus Reserpine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: 3. Deterioration ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alpha‐methyldopa versus Reserpine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000458-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DOPAMINERGIC DRUGS vs PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: 1. No clinically important improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.29, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Reserpine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.29, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: 2. Not any improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Reserpine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 L‐DOPA ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.35, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Carbidopa/levodopa ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.26, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: 3. Deterioration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.35, 3.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Reserpine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Carbidopa/levodopa ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.44, 7.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: Deterioration ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oxypertine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.2 [0.22, 22.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acceptability of treatment: Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.65, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amantadine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Bromocriptine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Tiapride ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Tiapride ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Oxypertine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.83, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Carbidopa/levodopa ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DOPAMINERGIC DRUGS vs PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000458-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">DOPAMINERGIC DRUGS vs OTHER DRUGS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tetrabenazine vs Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: 2. Not any improvement ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.05, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tetrabenazine vs Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.05, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: 3. Deterioration ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.09, 14.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tetrabenazine vs Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.09, 14.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acceptability of treatment: Leaving the study early ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tetrabenazine vs Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">DOPAMINERGIC DRUGS vs OTHER DRUGS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000458.pub3/references#CD000458-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000458.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000458-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000458-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000458-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000458-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000458\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000458\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000458\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000458\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000458\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000458.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000458.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000458.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000458.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000458.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727786168"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000458.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727786180"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000458.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb490cfd49368',t:'MTc0MDcyNzc4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 